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aa    Amino acid 
AF1     Activation function domain 2 
AF2    Activation function domain 1 
AP1    Activator protein 1 
Å    Ångström 
bp    Base pair  
BC    Breast cancer 
BRCA2   Breast cancer 2 early onset (Human gene) 
BRCA1   Breast cancer 1 early onset (Human gene) 
CREB    cAMP response element binding protein  
COACH   Meta-server protein-ligand binding site prediction 
DBD    DNA Binding Domain 
E1    Estrone 
E2    Estradiol 
E3    Estriol 
EDCs    Endocrine disrupting chemicals 
ER    Estrogen receptor 
ER-    Estrogen receptor negative 
ER+    Estrogen receptor positive 
ERE    Estrogen response element 
ERα     Estrogen receptor α 
ERβ    Estrogen receptor β 
ESR1    Estrogen receptor Alpha 
ESR2    Estrogen receptor Β 
GPER1   G protein coupled estrogen receptor 1 
Her-2/neu   Human epidermal growth factor receptor 2 
kDa    Kilo Daltons 
LBD    Ligand Binding Domain 
mM    Millimolar 





NTD    N-terminal Domain 
p53    Tumour protein p53 
PE    Phytoestrogen 
pH    Measure of the acidity or basicity 
RUNX1   Runt-related transcription factor 1 
SERM    Selective estrogen receptor modulator 
SNPs    Single-nucleotide polymorphism 
SP1     Specific protein 1 
STAT5   Signal transduction and activator of transcription 5 
TAM     Tamoxifen 
WHO    World Health Organization 
WT    Wild Type 








Breast cancer is one of the most common diseases affecting women and 
approximately 1.3 million females are diagnosed each year with this disease 
worldwide. Breast cancer is a multi-factorial disease and it is difficult to predict 
or control the physiopathology, to date one of the major risk factors alongside 
the patient’s genetic background is life time exposure to estrogen. 
Understanding the estrogen receptor (ER) has been a milestone in elucidating 
breast cancer biology, leading to advances in disease management. Alongside 
this, evidence from epidemiological studies suggests that dietary consumption 
of phytoestrogens may modulate disease progression. This study hypothesises 
that the interaction between some phytoestrogens (present in the pre-diagnosis 
diet or in the new diet adopted by breast cancer patients) and specific ER 
isoforms displayed in breast tumours influences the action of synthetic and 
endogenous estrogen in breast cancer cells. This study aimed to understand 
the interaction between estrogen, hormone drugs and phytoestrogens on the 
ER. In silico modelling of the ER focused on the wild type isoforms ERα and 
ERβ and different ligands (SWISS MODEL and docked through AutoDock 
Vina). Subsequently, isoforms of ERα and ERβ and different ligands (E1, E2, 
E3, PE, Tamoxifen, ICI 182,780) were modelled and tested by docking against 
the same set of ligands (E1, E2, E3, PE, Tamoxifen, ICI 182,780).  
 
The system described here highlighted the main amino acid residues of the LBD 
of ERα and ERβ along with ligand interactions for both agonists and antagonists, 
described in previous X-ray crystallography experiments. All of the 
phytoestrogens studied using AutoDock Vina interacted with the hormone 
binding site of both ERα and ERβ, due the phenolic ring of the studied structure 
which favoured the interaction with the hydrophobic environment of LBD amino 
acids. All of the dietary phytoestrogens showed lower binding affinity (<9.1 
Kcal/mol) compared with estradiol (-10.6 Kcal/mol) in all the isoforms and 
isotypes studied, suggesting that phytoestrogens should not displace estradiol 
from the LBD, however it remains unclear if PE can act as an agonist compound 
in the ER pathways. Also, some phytoestrogens appeared to have greater 
affinity to the ERα and ERβ than Tamoxifen (antagonist models), but it is 
uncertain as to whether the resulting structure will interfere with subsequent 
interactions. Further laboratory experiments will be necessary to understand the 
impact of the PE in the ERs structure and the respective role in the ER pathway. 
 
The data from this computer modelling approach has provided an insight into 
the interactions between endogenous estrogens, drugs, phytoestrogens and 
ER. The in silico studies generated a system that recapitulated data obtained 
by other research groups (experimentally) and will be of value as a screening 
tool for further studies of new drugs and exogenous estrogens and their 
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The aim of this project was to use in silico protein modelling and ligand docking 
techniques to evaluate the binding of physiological (endogenous) ligands of the 
ER alongside breast cancer drugs and dietary phytoestrogens. 
These aims were addressed as follows: 
 
Chapter 3: Identification and use of wild type human ERα and ERβ ligand 
binding domains (LBD) as a template for protein homology modelling studies. 
Evaluation of the binding of estrogens and drugs (Tamoxifen/ Fulvestrant) to the 
LBD of ERα and ERβ. 
 
Chapter 4: An in silico study of the interaction between dietary phytoestrogens 
and the LBD of wild type human ERα and ERβ. The development of protein 
homology models of the LBD of variants of ERα and ERβ. 
 
Chapter 5: In silico analysis of the interaction between dietary phytoestrogens 
















1.1 Breast cancer epidemiology 
Breast cancer is one of the most common diseases in women. Worldwide 
approximately 1.3 million females are newly diagnosed with breast cancer each 
year (Ferlay, Parkin, and Steliarova-Foucher 2010). Breast cancer is a 
heterogenous disease that has been classified into subtypes according to the 
level of estrogen receptor (ER), progesterone receptor (PR) and the epidermal 
growth factor receptor-2 protein (Onitilo et al. 2009; Weigelt et al. 2010). 
According to estimated projections in the UK, breast cancer prevalence may 
increase threefold from the incidence of approximately 50,000 patients reported 
in 2010 to 150,000 by 2040 (Maddams, Utley, and Moller 2012). Worldwide 
approximately 465,000 patients succumb to breast cancer per annum. Changes 
in reproductive patterns, sedentarism, obesity and breast cancer screening 
programmes are partly responsibility for the reported rise in breast cancer 
incidence (Bray and Møller 2006). Nevertheless, breast cancer incidence and 
mortality fluctuates worldwide and varies geographically from Western to 
Eastern countries (IARC, 2012), for example, in Sweden the breast cancer 
incidence has been reported as 153 cases per 100,000 whilst in China the 
estimated incidence is 24 cases per 100,000  (Leong et al. 2010). 
Simultaneously, it is worthy of note that even within in the same continent where 
the population share similar lifestyles and cultural backgrounds differences in 
incidence rates are reported, for example, in South America; in Argentina the 





Colombia the incidence was less than half this number with 31 cases per 
100,000 reported (World Health Organization WHO 2012). Overall, there has 
been a significant increase in breast cancer incidence globally during the past 
three decades; in developed nations this may reflect the adoption of screening 
programs resulting in the detection of asymptomatic (smaller and potentially 
less-aggressive) tumours (Holford et al. 2006), the trend toward decreased 
parity and age of first child, and in the developing world this reflects the decrease 
in communicable diseases and improvements in longevity. A breast cancer 
diagnosis brings vast changes to the lives of patients and individuals related to 
them and the disease continues to be a significant cause of mortality, hence a 
better understanding of even a single factor involved in breast cancer aetiology 
has the potential to make a great impact in both the diagnosis and the treatment 
of the disease.  
 
1.2  Role of estrogen in breast cancer risk and disease progression 
The hormone estrogen, the estrogen receptors (ER) and their downstream 
molecular components all play an important role in breast cancer development 
and progression - approximately 70% of all primary breast cancers have been 
shown to be estrogen receptor positive, ER+ (Hüsing et al. 2012). Following the 
binding of estrogen to the ER a series of intracellular events occur and these 
lead to cellular proliferation – a key hallmark of cancer(Hanahan and Weinberg 
2000, 2011). The greater the rate of cell proliferation, so the increased chance 
that damage to DNA is inherited by daughter cells as a result of reduced time 
for DNA repair. The more prolonged exposure an individual or a population of 





increases.  Such estrogen related risk factors include early menarche and late 
menopause  (Bernstein and Ross 1993), later age of first child, decreased 
numbers of full term children, breast feeding, nullparity and use of hormonal 
replacement therapy(Chen and Colditz 2007; King et al. 2011). 
  
The incidence of ER+ breast cancer is increasing in urbanised developed areas 
as well as in developing areas (Leong et al. 2010) suggesting that environment 
and lifestyle play an important role in the potential initiation of breast cancer 
(Cavallo et al. 2011; Giulivo et al. 2016). Environmental factors that affect or 
mimic the action of estrogen may act as carcinogens; substances include 
endocrine disrupting chemicals (EDCs), xenoestrogens and exogenous 
estrogen (Fernandez and Russo 2010; Liu et al. 2015). Although  studies with 
xenoestrogens have not yet reported consistent associations between exposure 
and breast cancer incidence (Fernandez and Russo 2010) this may be due to 
specific effects of the estrogen-like chemical(s) in only a particular subtype of 
breast cancer, or may be due to synergism with others risk factors which have 
not been considered in the studies to date. 
 
1.2.1 Estradiol 
The endocrine system plays an essential role in human physiology and is key 
for a wide range of metabolic functions playing a pivotal role in reproduction, 
growth and development.  Amongst the estrogens, estradiol, E2, is the most 
potent and most closely correlated with hormone-dependant breast cancer 
(Hall, Couse, and Korach 2001) as well as with other diseases such as 






Estradiol has a molecular volume of 245 Å and as a result of its phenolic 
structure is relatively lipophilic (Anstead, Carlson, and Katzenellenbogen 1997). 
Studies with structural models of ERs that have been built in complex with 
estradiol have helped to provide an understanding of the binding site of these 
receptors. Knowledge of the structure of the ER as well as the biochemical 
pathways leading to the in vivo synthesis of estrogens have led to the 
development of drugs targeting the receptors as well as estrogen biosynthesis; 
many of these have found their way into clinical use as breast cancer treatments 
(Smith et al. 2003). 
 
The ovaries are the main source of estrogen but the conversion of precursor 
molecules to estradiol can also occur in other tissues. Numerous enzymes 
involved in the biosynthesis of estradiol (E2) and (the less active estrogen) 
estrone (E1) have been described, these include the hydroxysteroid 
dehydrogenase family and the aromatases.  The release of estradiol by 
aromatase enzymes, particularly from adipose cells, is an important source of 
estrogen in postmenopausal women (Brueggemeier 2001) and provides a 
rationale for the approximate three-fold increased risk of breast cancer 
associated with obesity (Ziegler et al. 1996).   
 
Estrone is usually stored in the breast in an inactive form as estrone sulphate, 
this is then reduced by the dehydrogenase enzyme (17β) to the more potent 
estradiol which interacts with ERs resulting in cell proliferation (Pike et al. 1999). 
The estradiol exerts its effect by docking into the ligand binding domain (LBD) 
of ER, ligand-dependant transcription is followed by gene activation at estrogen 





responsive genes resulting in DNA replication and leading to cell proliferation 
(Flötotto et al. 2004). 
 
1.3 ER in breast cancer aetiology 
Until the 1960s it was believed that estrogens were only involved in the sexual 
reproductive system through oxidation-reduction pathways but in 1962 Jensen 
et al used tritiated estradiol and reported the uptake of the tritiated compound in 
uterine and vaginal tissues but not neighbouring normal tissues (Jensen and 
Jacobson 1962), subsequently Noteboom and Gorski, 1965, proposed that 
tritiated estradiol interacted with a receptor which was likely to be a protein (Toft 
and Gorski 1966).  
 
The ER was first described as such in 1985  (Green et al. 1986) and at that time 
was thought to comprise a single protein, now known as ERα, since at that time 
an additional form of ER (ERβ) was discovered  (Bakas et al. 2008; Kuiper et 
al. 1996) alongside a number of splice variants and also single nucleotide 
polymorphisms (SNPs) in the genes for ERα and ERβ themselves.   
 
ERα has been shown to have the greatest affinity to 17β-estradiol but it can also 
interact with a wide range of compounds; altering normal pathways activated 
following estrogen binding.  The interaction between the different ER isoforms 
with both endogenous and exogenous estrogen may vary according to the 
cell/tissue. The complexity of different pathways activated by specific ligands 





major challenge for scientists who aim to gain a fuller understanding of 
estrogenic pathways. 
 
1.3.1.1 Targeting ER in breast cancer  
Recognition of the importance of estrogen as a mediator in breast cancer led 
initial surgical treatments to reduce levels of circulating estrogens by removal of 
the ovaries (ovarian ablation/oophorectomy) and although the studies using this 
approach were small, improved survival after breast cancer was observed in 
women less than 50 years of age (reviewed in Schiavon & Smith, 2014).  These 
initial studies led to the development of endocrine therapies for breast cancer 
which have made a lasting impact on the care of patients with breast cancer. 
The treatment of breast cancer encompasses surgical, radiological, 
chemotherapeutic, biological as well as hormonal therapies and since the 1970s 
the 10-year survival rate after a breast cancer diagnosis has more than doubled 
to approximately 80% (Cancer Research UK 2012).  
 
The first important drug developed targeting the ER was Tamoxifen, a 
triphenylethylene derivative, initially known as ICI 46,474, Tamoxifen had been 
developed by ICI as a morning-after pill but studies in this setting proved 
unsuccessful. Craig Jordan and colleagues used a rodent model of mammary 
carcinoma and were the first to show the potential of Tamoxifen as a treatment 
for breast cancer (Jordan 2004). Tamoxifen is metabolised to 4-hydroxy 
Tamoxifen and 4-hydroxy N-des-methyl Tamoxifen in the liver by enzymes of 
the cytochrome P450 system (CYP2D6).  The active 4-hydroxy forms are 
selective estrogen receptor modulators (SERM) and act as antagonists of ER in 





patients have shown the importance of Tamoxifen as a first-line therapy for pre-
menopausal breast cancer (with ovarian ablation) (reviewed in Schiavon & 
Smith, 2014).  
 
The development of Tamoxifen paved the way for other selective estrogen 
receptor modulator compounds (SERMs) such as Raloxifene and the “pure 
antagonist” Fulvestrant: ICI 182,720 (McDonnell and Wardell 2010).  At a 
molecular level SERMs function by blocking the activation domain (AF2) of the 
ER by displacing helix 12, rotating it by 110° thereby rendering the binding site 
for the co-activator protein p160 inaccessible (Kushner et al. 2000).  
 
A class of compounds known as aromatase inhibitors (AIs) have been 
developed for use in post-menopausal women. AIs include anastrazole, 
letrozole and exemestane, these bind to aromatase and prevent the synthesis 
of estrogens from parent compounds such as androgens and have proved to be 
a very successful class of drugs (Dowsett and Howell 2002). Rather than acting 
directly as SERMs these compounds work “upstream” preventing the synthesis 
of endogenous estrogens.  
 
It has been estimated that up to 40% of all cases of ER+ breast cancer become 
resistant to long term treatment with Tamoxifen (Shou et al. 2004). The reasons 
for the development of such resistance is not clear but may include: selection 
pressures favouring ER negative breast cancer cells; cross-talk between 
different signalling pathways; the presence of ER negative stem cells and 
interactions between different isoforms of the ER with endogenous and 






The complexity of different pathways activated by specific ER ligands alongside 
the presence of different heterodimers and SNPs poses a major challenge for 
scientists who aim to gain a fuller understanding of estrogenic pathways, 
resulting in more aspects to investigate and study, and the opportunity to 
develop approaches for novel breast cancer treatments focusing on, for 
example, SERMs tailored to patients with different isoforms of the ER and 
genetic variants (SNPs). 
 
1.3.2 Phytoestrogens and the diet 
The term phytoestrogen encompasses a wide range of phenolic compounds 
called flavonoids, they are low molecular weight compounds with estrogen-like 
properties due to  the presence of the phenolic ring A and the similar distance 
between the 7 and 4 hydroxyl groups in the isoflavones when compared with 
the hydroxyl groups of estradiol (Dixon 2004). Phytoestrogens are secondary 
metabolites and dietary sources include cruciferous vegetables, seeds, fruits, 
coffee, soy beans, berries and flowers (Middleton, Kandaswami, and 
Theoharides 2000).  
 
Isoflavonoids are naturally-occurring polyphenolic compounds, mainly found in 
the Leguminosae. Some isoflavanoids have been found to bind to the human 
ER with an affinity similar to that of estradiol (Davies, Batehup, and Thomas 
2011). Soy-containing foodstuffs are enriched in isoflavones and are an 
important source of dietary phytoestrogens (Velentzis et al. 2011). Isoflavone-
containing foods are consumed in Asian countries, particularly China and Japan 





genistein and glycitein (Banerjee et al. 2008) may at least partly explain  the 
lower incidence of breast cancer in these countries (Caan et al. 2011). Aside 
from the ingestion of daidzein and genistein the gut microflora of approximately 
30% of humans produces metabolites such as enterolactone and equol and 
these metabolites have been thought to bind to the ER with greater affinity than 
the parent compound (Setchell and Clerici 2010). It is not known if the 
association between high consumption levels of dietary phytoestrogens and 
reduced incidence of breast cancer is linked to the ability to metabolise daidzein 
into equol (Cederroth and Nef 2009). Daidzein, genistein and equol appear to 
show greater affinity to the ERβ than ERα(Kuiper et al. 1998; Lund et al. 2004).  
 
1.3.2.1 Bioavailability and metabolism 
Phytoestrogens are often classified according to the number of substituents on 
their ring structures and the most important groups arising from such 
classification are the flavones (apigenin), flavanones, flavonols and isoflavones 
(biochanin A, formononetin, genistein, daidzein and glycitein), coumestan 
(coumestrol), and lignans (secoisolariciresinol, matairesinol, enterolactone, 
enterodiol) (Romano et al. 2013). Dietary phytoestrogens are found either in a 
free-state or in a more stable state bound to a sugar, leading to relatively low 
bioavailability after ingestion. The ratio of bound versus glycone free forms of 
phytoestrogens varies according to the food source itself.  Fermented soy-
based food stuffs tend to have higher levels of glycone free isoflavones although 
the conjugated form can be deconjugated by the intestinal microbes after 
consumption (Axelson et al. 1984). Further complexity arises as phytoestrogens 
such as biochanin A and formononetin can be metabolised to genistein and 





et al. 1984). However, to produce the metabolite equol and its alternative O-
desmethylangiolensin (O-DMA) from daidzein, specific types of (as yet 
unidentified) intestinal bacteria are required (Rafii 2015) but these are present 
in only 30-50% of the population (Setchell and Clerici 2010). Determining the 
“equol metabolism” status of an individual is of some relevance since equol has 
been shown to exhibit greater estrogenic potency than daidzein (Setchell and 
Clerici 2010). Besides their affinity for the ERs phytoestrogens can affect the 
metabolism of the steroid hormones as they act as natural anti-oxidants and as 
anti-inflammatory compounds having been reported to affect a wide range of 
signalling pathways resulting in reduced inflammatory responses in cells 
(Hwang and Choi 2015). 
 
1.3.2.2 Phytoestrogens and breast cancer 
The role of the phytoestrogens in disease prevention has been the subject of 
over a thousand scientific peer-reviewed publications and their role in breast 
cancer risk reduction and breast cancer outcomes have been the subject of 
study by many research groups. Over the past two decades studies have been 
concerned with both molecular and cellular as well as whole-individual and 
population studies(Bliedtner et al. 2010; Ganry 2005; Harris and Besselink 
2005; Rice and Whitehead 2008; Romano et al. 2013). 
 
In terms of breast cancer incidence, a lower level of phytoestrogen consumption 
is found in Western diets (Chun, Chung, and Song 2007) where breast cancer 
is more prevalent compared with Eastern countries where there are much higher 
levels of consumption of phytoestrogens reported and lower breast cancer 





countries with higher breast cancer incidence levels so the next generation 
adapts their diet consuming the lower levels of phytoestrogens associated with 
the behaviour in Westernised countries (Shimizu et al. 1991).  The serum levels 
of estradiol are 40% lower in Asian women compared with the levels in Western 
women (Peeters et al. 2003). In addition, women in Western countries tend to 
consume lignans as well as isoflavones in their diet further adding to the 
complexities associated with studying this area of biology (Swann et al. 2013).  
 
The effect of dietary phytoestrogen consumption on breast cancer survival 
remains unclear.  A large meta-analysis reported by the World Cancer Research 
Fund in 2014 disappointingly concluded that more research is still required on 
this topic (Cancer Research UK, 2014). A number of on-going studies including 
the UK-based DietCompLyf study (Swann et al. 2013) and the After Breast 
Cancer Pooling Project (Nechuta et al. 2013) seek to explore this topic in more 
detail as both dietary and environmental factors have been estimated to play a 
major role in outcomes after breast cancer. 
 
It remains unclear as to the functional role of phytoestrogens in breast cancer 
progression since the data produced related to phytoestrogens are inconsistent 
between in vitro and in vivo systems.  Phytoestrogens such as daidzein and 
genistein have been suggested to function as SERMs and this may relate to 
their tissue specific effects, for example, agonistic activity in bone related to 
osteoporosis, whilst antagonistic activity in breast tissues inhibiting breast 
cancer.  The isoflavones have been shown to act in an agonistic fashion towards 
human breast cancer cell lines (Simons et al, 2011). Genistein functions in vitro 





pathway which is over-expressed in many cancer including breast cancer 
(Akiyama et al. 1987; López, López, and Arias 2015)(Akiyama et al. 1987; López 
et al. 2015). Also, it has been reported that genistein acts as an anti-proliferative 
agent at more than 10 mM concentration but at low doses in vitro it acts as a 
tumour agonist (Wang, Sathyamoorthy, and Phang 1996). Further research 
should help to unravel the effect of isoflavones on malignant cells and produce 
data related to the benefits and/or adverse effects that arise from phytoestrogen 
exposure. 
 
1.3.2.3 DietCompLyf study 
The DietCompLyf study is a multi-centre observational study that was run by the 
Against Breast Cancer Research Unit at the University of Westminster. The 
study is focussed on determining the role of PEs on BC recurrence in a UK 
population (Velentzis et al. 2011)(Velentzis et al., 2011). A key element of the 
DietCompLyf study is the availability of reported food intake alongside biological 
samples enabling analysis of PE intake, biomarker levels and correlation with 
clinical treatments and patient recurrence rates. The findings of the in silico and 
in vitro experiments will be compared with data and samples collected as part 
of the DietCompLyf study. The database of the DietCompLyf study counts 
comprises around 3,169 women. A separate nested case control cohort of 
around 200 patient matched with all the clinical criteria is available. All the 
subjects have provided a food frequency questionnaire, and a 7-day food diary 
allowing PE levels to be estimated in addition their urinary PE levels which have 
been quantified by liquid chromatography/tandem mass spectrometry(LC–






1.4 ERα and ERβ  
Of the two ER subtypes, ERα is mainly expressed in the human breast, uterus, 
cervix and vagina, while ERβ is mainly found in the spleen, lung, hypothalamus, 
thymus, immune and central nervous systems, urogenital tract (ovary, prostate, 
and testis), bone and kidneys (Couse et al. 1997). The selective expression of 
the two main forms of ER leads to specific ligand action in each of these tissue 
types. Both of the major subtypes of ERs have been identified in breast cancer 
(Fixemer, Remberger, and Bonkhoff 2003). Despite being encoded by different 
genes (ERα: ESR1 gene and ERβ: ESR2 gene) and on different chromosomes, 
6 and 14 respectively (Barnes 2010), both receptors have structural similarities 
and a high degree of homology as shown in Figure 1.  
 
Figure 1. Structure of estrogen receptor alpha (ERα) and estrogen 
receptor beta (ERβ). Amino acid positions for the structural motifs are 
displayed above each protein. The percent amino acid homology is given under 
ERα and ERβ. 
 
The DNA-binding domains (DBD) of human ERα and ERβ show 96% amino 
acid homology. Whilst ERα and ERβ share a homology of 54% in the ligand 





in both subtypes  (Huang, Chandra, and Rastinejad 2010) but each receptor 
regulates specific genes and displays a different profile of gene networks 
following activation (Eyster 2016).  The major difference between the sequences 
for ERα and ERβ is in the activation factor (AF-1) domain which relates to 
hormone independent transcription activity. ERα and ERβ have been reported 
to be co-expressed, acting as homo- or hetero-dimers although the impact on 
cellular pathways has not yet been unveiled.   
 
ERs are members of the nuclear receptor superfamily sharing common regions 
(A/B, C, D, E and F regions) which form independent but interacting functional 
domains; N-terminal domain (NTD); DBD; LBD and two activation function 
domains AF1 and AF2, located in NTD and LBD, respectively. The AF1 domain 
recruits co-factors independent of ligand binding and AF2 recruits co-factors but 
is dependent on ligand binding (Kumar et al. 2011). AF1 and AF2 together are 
responsible for the regulation of receptor activity during transcription. A number 
of important co-activators have been described for ER including: SCR-1 / 
NCoA1 and SCR-2 / TIF2 / GRIP1 / NCoA-2, these bind a hydrophobic groove 
in the receptor termed the LXXLL motif, the co-activator/ER complex then leads 
to gene transcription by virtue of recognition of estrogen response elements 
(EREs) (Gruber et al. 2004).   Another mode of action is via interaction between 
ER and transcription factors for example: AP1, SP1, NF-kB, CREB, RUNX1, 
p53 and STAT5, these bind the ER following ligand-ER complex formation 
(Kushner et al. 2000).  This recruitment of transcription factors leads to gene 
transcription in genes that lack EREs. ERs exhibit a high degree of plasticity 
interacting with different ligands ranging from natural endogenous estrogens to 





leading to a conformational change in the LBD domain and enabling co-activator 
interactions with ER (Shiau et al. 1998). Understanding the molecular 
interactions between the range of ligands in nature, their effect on the molecule 
structure of ER and pathways activated down-stream of ligand binding will be 
an important tool in understanding breast cancer development and may offer 
potential for the development of breast cancer treatments. 
 
1.4.1 ER ligand binding domain (LBD) 
The LBD of ERα and ERβ are only 54% similar at amino acid residues 302 to 
552 and 255 to 504 in ERβ (Kuiper et al. 1996) leading to different outcomes 
(agonist or antagonist) from the two forms of this receptor despite interaction 
with the same ligand. When the 3D structure is considered, despite the low 
degree of sequence homology, the nuclear receptor superfamily display a highly 
degree of similarity in terms of conformation of the LBD. In ERs the LBD is 
formed by eleven helices (H1 to H11) contained within the ligand binding site, a 
further helix (H12), a dimerization interface and co-regulator interaction is sited 
within a globular structure (Moras and Gronemeyer 1998). 
 
The helices found within the ER LBD are arranged in three layers in agonist 
conformation with helices H4, H5, H6, H8 and H9 lining up on one side, H1 and 
H3 and on the opposite side helices H7, H10 and H11. H12 sits on the binding 
site cavity against H3, H5/6 and H11 without making contact with the ligand and 
forming a lid-like structure in the binding pocket and contributing to the 
hydrophobic microenvironment within the cavity, becoming an essential 
component for binding to partner proteins for later transcriptional activation 





with chaperon proteins (Heat shock proteins 70 and 90) mainly interacting with 
the LBD of the protein (Pratt et al. 2004) upon ligand binding, the ER structure 
displays structural modifications leading to homo- (ERαα and ERββ) and hetero- 
(ERαβ) dimerization and nucleus translocation.  
 
1.4.2 Mechanism of action ER 
Several genes are regulated by ER and these can be identified by the presence 
of EREs or by the binding sites for a range of transcription factors which have 
been recognised to bind to ER. The classical pathway has a more limited range 
of targets when compared to ER activity at alternative response sites 
(Bjornstrom and Sjoberg 2005)(Bjornstrom and Sjoberg 2005). The effects of 
estradiol occur through at least four pathways, Figure 2. 
 
Figure 2. Mechanism of estrogen receptor signalling. 1. Ligand-
independent: intracellular kinase pathways are activated by growth factors and 
cyclic adenosine monophosphate (CAM) phosphorylation (P) leading to the 
activation of ER and ERE binding in a ligand-independent fashion. 2. Non-
genomic signalling: Estrogen activates a form of ER linked to intracellular signal 
transduction generating a tissue response. 3. Ligand-dependent: E2-ER binds 
to EREs leading to up- or down-regulation. 4. ERE-independent: E2-ER 
associates with DNA transcription factors FOS/JUN tethering ER to alternative 






In the ligand-independent pathway ERs may be activated by epidermal growth 
factor (EGF), insulin-like growth factor-1 (IGF-1) and 8-bromo-cyclic adenosine 
monophosphate, activating intracellular kinases  leading to protein 
phosphorylation, which then increases gene expression by ER activation (Hall 
et al., 2001; Thomas and Gustaffson, 2011). In a further pathway the E2-ER 
complex can induce gene expression even in the absence of direct DNA binding 
(Kushner et al., 2000), furthermore cell-surface signalling may occur. ERs are 
associated with signalling pathways functioning via cell membrane receptors, 
for example, CPCRs, ion channels and protein tyrosine kinase pathways 
(Simoncini and Genazzani 2003). 
 
After ligand binding, the receptor undergoes a conformational modification 
whereby the chaperon protein heat shock protein 90 (Hsp-90) is released 
resulting in the nuclear translocation of ER dimers, binding with high affinity to 
specific nucleotide sequences in palindromic motifs (EREs) and recruitment of 
co-activator or co-repressor molecules resulting in gene expression or 
preventing transcription according to the nature of the ligand, agonist or 
antagonist, respectively (Dao and Hanson 2012). The alpha helix 12 at the LBD 
plays an important role at this stage allowing or preventing the interaction of the 
transcription complex. In the genomic pathway ERs can regulate transcription 
without binding to DNA, instead tethering receptors through protein to protein 
interactions to a transcription factor contacting the DNA. A large number of 
estrogen-responsive genes not containing ERE sites are modulated by this 





and Sjoberg 2005). Subtypes of ER are able to mediate the non-genomic effects 
of estrogens within less than 15 minutes after estrogen treatment through ion 
movement through the membrane (Marino et al., 2006; Kampa et al., 2013).  It 
appears, however, that the ligand binding domain of ERα targeted to the plasma 
membrane is sufficient for the regulation of non-genomic activity of estrogens 
(Adlanmerini et al. 2014). 
 
1.4.3 ERα isoforms  
Despite being encoded on different chromosomes by different genes: ERα, 
ESR1 and ERβ, ESR2, ERα on chromosome 6 and ERβ on chromosome 14 
(Barnes, 2010), the receptors show structural similarities and a high degree of 
homology as described above.  
 
1.4.3.1 Estrogen receptor alpha isoforms 
Wild type ERα66 is the most prevalent form in BC cells, other isoforms have 
been reported as involved in cancer pathology (ERα46, ERα36, ERαΔ5/6/7, 
ERαΔ3/4/5, ERαV) (Flouriot et al. 2000; Marino, Galluzzo, and Ascenzi 2006; 
Rao et al. 2011) ERα36 has been reported to interfere with ERα66 activity and 
the estrogen treatment in BC. (Wang et al. 2005). ERα36 is an isoform of ER-
α66 cloned in 2005 by Wang et al. (2005) which lacks both activation domains 
while retaining a DNA binding domain, ligand binding domain and partial 
dimerization, and is found in both the cytoplasm and cellular membrane. This 
might indicate its involvement in both genomic and non-genomic pathways 
(Bjornstrom and Sjoberg 2005). There is evidence that ERα36 possesses a 
broader activity spectrum than ERα66, initiating membrane-linked signalling in 





DNA-binding elements, and its expression appears to be related inversely with 
ERα66 expression. At UNIPROT Database ERα isoform 1 or wild type has been 
chosen as a canonical form due to its similarity to orthologous sequences found 
in other species, by lengths and amino acid composition. ERα isoform 1, also 
known as a ERα66 or hER-alpha66, was isolated and sequenced in MCF-7 
covering the entire mRNA and expressed in HeLa cells (Greene et al. 1986). 
ERα isoform 2 (known as a short ERα) and comparing with the canonical form 
this isoform is missing the amino acid residues 255 to 366 and has a molecular 
weight of 53 KDa in comparison with the wild type which is 66 KDa. ERα isoform 
3, also known as hER-alpha46 or ER46 due to its molecular weight of 46 KDa, 
is missing the N-terminal 173 amino acids encoded by a transcription factor 
which lacks the exon 1. ERα isoform 3 is a potent inhibitor of ERα66 isoform 1 
when transactivation AF1 is predominant over AF2 hence heterodimerization 
may play an important role in this context or simply binding competition for ERE 
(Flouriot et al. 2000). The ERα isoform 4 also known as hER-alpha36 or ER36 
lacks of both transcriptional activation (AF1 and AF2) domains and a unique 
sequence of 27 amino acid residues replaces the last 138 amino acids of the 
canonical sequence (ERα isoform 1) (Wang et al. 2005). ERα isoform 4 
activates non-genomic pathways hence inducing cell proliferation. Also, this 
isoform has been detected in ERα positive and ERα negative BC patients. 
Knocking down its expression in BC cancer cells was reported to decrease in 
cancer cell migration, invasion and increase the response of BC cells to 







1.4.3.2 Estrogen receptor beta isoforms  
ERβ acts as an antagonist of ERα in some estrogen stimulated cells. ERβ was 
described in 1996 and in 1998 five isoforms of ERβ were identified (ERβ1-5, 
where ERβ1 was the wild type and ERβ5 was already known as a ERβcx) 
(Moore et al. 1998).   ERβ1 is the only ligand dependant transcription isoform 
though all the isoforms can participate in hetero-dimerization with ERα and ERβ 
subtypes, negatively impacting transcriptional activity (Shanle and Xu 2010). 
ERβ1 is linked to better survival in triple-negative BC as well as better response 
to Tamoxifen monotherapy, while nuclear ERβ2 levels have been shown to be 
associated with metastasis and vascular invasion, also, cytoplasmic ERβ2 is 
linked to a poorer outcome in BC (Nilsson, Koehler, and Gustafsson 2011). 
Studies of ERβ remain a focus of clinical research, isoforms ERβ1 and ERβΔ5 
are co-expressed in healthy mammary glands (Mandušić, Nikolić-Vukosavljević, 
Tanić, Ksenija, et al. 2007); in particular, ERβΔ5 may has inhibitory activity on 
both ERα and ERβ, and its higher expression is linked to indicators of low 
aggressiveness of the tumour. Levels of ERα and ERβ decline with progression 
of disease in a subtype specific manner. Adverse effects of estrogens upon 
expression of ERα is observed in most cancers. On the other hand, the 
activation of WT ERβ has been linked with beneficial estrogenic activity, 
supporting the rationale of ERβ agonists for treating this disease. ERβ isoform 
1 known as Wild type or ERβ1 has a molecular weight of 60 KDa and it is 
considered the canonical sequence of the ERβ. ERβ isoform 2 is called ERbeta-
2 or CX which is truncated at the N-terminal and differs from the canonical 
sequences at the amino acid residues 469 to 530 and was described along with 
ERβ isoform 4, 5 and 6 (also known as beta 3, beta 4 and beta 5 respectively). 





though the last 61 amino acid residues at the C-terminal are replaced but a 
unique sequence of 26 amino acids. It has been reported that ERβ2 inhibits E2-
Transcription activation when it is co-expressed with the ERα isoform 1, possibly 
by competition in the ERE binding site or transcriptional silencing (affecting co-
activators or ER-related basal transcriptional factors), without discarding the 
possibility that ERβ isoform 2 acts through a novel pathway, ligand binding effect 
or specific ERE (Ogawa et al. 1998). ERβ isoform 1 prefers to dimerise with its 
own isoform overall ERβ isoform 5 and ERβ isoform 6 leading to a higher 
transactivation activity than the normal ERβ isoform 1 homo-dimerization 
(Nettles et al. 2008).The presence of more isoforms of ER and changes in the 
ratio ERα:ERβ isotypes and isoforms following by subsequent hetero or homo-
dimerization alongside varying levels of expression in different cells/tissues 
provides an opportunity for a better understanding and development of different 
approaches for improving prognosis and treatment of cancer. 
 
1.5 Modelling three dimensional protein structure and structure-based 
studies  
The study of bio-active molecules through several fields including drug 
discovery has contributed to the understanding of how they can influence 
physiological pathways. One target could align several molecules as a ligand, 
which could play different roles such as agonist, antagonist or to have multiples 
effects on disease progression (Feixas et al. 2014). A description and 
characterization of the diverse ligand-protein interactions will be important to 
understand biological function and downstream effects. Protein three-
dimensional structures have played a major role in the functional annotations, 





structures and known protein sequences is increasing. Although, the amino acid 
sequence of a protein determines its three-dimensional structure, the 
mechanism of protein folding is not completely unravelled. The structures of 
protein families members are more conserved than the sequences (Chothia and 
Lesk 1986) hence sequence similarity means structural similarity as well. 
Several computational methods have been used to predict 3D protein models 
(Template-based or homology methods and de novo modelling). De novo 
methodologies are based on the folding process simulation using the protein 
amino acid sequence as a starting point followed by the structure prediction with 
the lowest free energy structure without template from first principle (Bradley, 
Misura, and Baker 2005). Despite the challenge de novo approaches to 
understanding the protein folding has displayed recent success in structure 
prediction (Khoury et al. 2014) yet there is no method that can accurately predict 
protein structures without a template. On the other hand, homology modelling is 
considered the most common applied method due to its high accuracy in 
comparison with de novo methods. 
 
1.5.1  Homology modelling  
Homology modelling relies on experimental structures of homologous proteins 
to provide protein models that ideally should match the accuracy of the 
experimental model. Homology modelling has helped researches to narrow the 
space between structural space and protein sequences leading to production of 
models of proteins that have been difficult to crystallize or determine by NMR 
spectroscopy. Starting from the fact that protein sequences that are evolutionary 
connected will show similar 3D structures(Chothia and Lesk 1986) known 





experimental structures. Homology models can be used for a wide range of in 
silico experiments from drug screening to support experimental data in 
crystallography (Geromichalos 2007; Uchoa et al. 2004). In fact, homology 
modelling requires several systematic steps to reach more accurate and reliable 
models: template identification, sequence alignment, back bone generation, 
loop modelling, model optimization, validation and iteration.  
 
Validation of a model is highly relevant when models are used for structural-
based studies and screening. Models accuracy tends to be lower that the used 
template or parent structure yet low quality models still can be used for in silico 
experiments such as mutagenesis experiments. However, to perform structural-
based virtual screening (SBVS) high accuracy models are needed (Fan et al. 
2009), when a high-quality models are built it can be comparable with medium 
resolution X-ray crystallography structures.  
 
1.5.1.1 SWISS-MODEL 
Several in silico tools and user-friendly web servers have been developed to 
facilitate researchers to either allow the modeller to go step by step in the 
building process of the models ranging from template selection to model 
validation or automated/semi-automated web-servers that aim for the model 
through specialised algorithms to provide and resolve critical choices to help an 
inexpert modeller. 
 
SWISS-MODEL (Biasini et al. 2014) is a user-friendly automated web server 
interface that can generate homology protein models through the integration of 





assessment. The main steps for homology modelling are template identification, 
sequence alignment, modelling and model validation. Template identification 
can be performed based on the target sequence using BLAST (Altschul et al. 
1997) E-value as a limit, sequence alignment can be reliable only at >50% 
identical amino acid residues (Rost 1999) but alongside BLAST a search for 
reliable templates is performed against a library of Hidden Markov Model 
(Söding 2004) method to detect distance relationships between target and 
possible template even if part of the target sequence has not been uncovered 
yet. E-value score is used to rank the results of the template searching and after 
finding the template with significant sequence similarity and respective 
sequence alignment template-target, the model coordinates are built based on 
the protein structure conserved regions between target and template by 
ProMod3 (Biasini et al. 2014) and energy minimized using Gromos force field 
(Christen et al. 2005). For each model built its respective quality estimation will 
be provided with local and global estimates, QMEAN and QMEAN Z-score 
respectively.  
 
1.5.1.2 Model quality assessment: QMEAN and QMEAN Z-score 
Local and global quality of the models is assessed by the quality model energy 
analysis (QMEAN) scoring function, this assesses important aspects of the 
protein structure to identify the native structures among the generated models, 
which cover three statistical potential terms and the agreement of the predicted 
secondary structure and  solvent accessibility (Benkert, Tosatto, and 
Schomburg 2008) including: 
• The torsion angle potential: extended torsion potential over three 





• Solvation potentials: Cβ atoms, the potential reflecting the degree of 
solvent exposure (in a sphere of around 9 Å) for a given amino acid 
residue. 
• Distance dependent pairwise potential: pairwise α/β, residue-specific 
pairwise distance-dependent potential using C α and β as the interaction 
centre; secondary structure specific implementation of the residue-level 
pairwise potential for long range interactions. 
• Secondary structure and solvent accessibility agreement: secondary 
structure implementation for derivation and application of the potential 
agreement of the target-sequence calculated secondary structure using 
PSIPRED (Jones, 1999) and agreement of the predicted binary burial 
status  provided by ACCpro (Cheng et al., 2005) to calculate the solvent 
accessibility cut off at 25%. 
 
In order to assess protein models independent of size it is needed to estimate 
the absolute model quality by relating the features of the predicted model to 
experimental structures of similar size based on QMEAN score leading to a 
QMEAN Z-score (estimate of degree of nativeness or deviation from native 
behaviour). Scores of single body potentials are normalised by the number of 
amino acids residues and the score of the interaction potentials (atoms and Cβ 
potentials) compared with the number of interactions in order to correct the size 
dependence of the potential scores (Benkert, Biasini, and Schwede 2011). 
QMEAN is an important tool for model quality assessment in homology 





different terms and QMEAN Z-scored provides data about the absolute quality 
of the predicted homology models. 
 
1.5.2 Molecular Docking       
Molecular docking is an approach that is able to compute stable and 
energetically favourable poses of a specific ligand in complex with a protein 
structure. Sampling or search algorithms are responsible for exploration of the 
motion space and is able to score and generate energy binding data of the 
complex, ligand conformation and orientation (Elokely and Doerksen 2013). In 
order to predict the conformation of the receptor-ligand complex a computer 
simulation procedure is needed. Each docking software needs one or more 
search algorithms to predict possible conformations. These methodologies can 
be divided in three groups; systematic methods (Matching algorisms and 
incremental construction), stochastic methods (Monte Carlo and genetic 
algorithm) and simulation methods (molecular dynamics and energy 
minimization) (Kitchen et al. 2004). Matching algorithms are used where the 
ligands are treated as pharmacophores and hydrogen bonds are taken into 
account for the calculations (DOCK). Incremental construction methodology is 
where the largest fragment is used as an anchor and the remaining fragments 
are added incrementally (FlexX). LUDI fragments are fitted in the binding site to 
evaluate interaction sites to finally connect all the single fragments into a final 
molecule. Stochastic methods randomly change a ligand conformation to 
explore the conformational space. Monte Carlo and genetic algorithms belong 
to this method group. Monte Carlo methodology is based on the production of 
poses through bond rotations or rigid body and conformation are assessed with 





theory of evolution (Meng et al. 2011). In simulation methods, molecular 
dynamics is the most used approach though it is computationally exigent and 
time consuming and may not be able to fit the ligand into the target and usually 
simulation methods are more used to complement other algorithms and 
methodologies. After docking the ligand in the protein it is necessary to rank and 
evaluate the potential binding modes. After estimating prediction of the binding 
conformation, is necessary to discern between correct and false poses. This 
calculations are mainly divided in three groups: force field-based (quantification 
of ligand-target complex energy and internal ligand energy), empirical 
(regression analysis using experimental pre-calculated binding data) and 
knowledge-based scoring function (pairwise atoms potential to evaluate ligand 
binding interaction. 
 
1.5.2.1 AutoDock Vina 
AutoDock Vina is an open-source software that has been widely used in 
research and academia. Vina can be used for a docking single ligand at a time 
or for virtual screening with the support of the MGL tools (Forli et al. 2016). 
AutoDock is a suite of automated docking tools. AutoDock combines an 
empirical force field with Lamarckian genetic algorithms (Morris et al. 1998). 
Providing fast prediction for bound poses or conformations alongside free 
energies score. Through the use of grid-based method autodock that allow an 
efficient evaluation of the motion space of the protein binding site and the 
binding energy of the conformations. In this method the protein is embedded in 
a grid, in which the protein is embedded in a grid to search the entire 
conformational space around a protein available to a ligand. At this point, a 





between probe and target and the value is stored and remains available to refer 
to during the docking simulation. Although the use of the grid treats the target 
protein as rigid, the ligand is flexible and only torsional degree of freedom are 
used keeping bond lengths and bonds angles constant (Cosconati et al. 2010). 
The Lamarckian genetic algorithm is the principal method for conformational 
searching, where a population of "trial" conformations is generated and mutates 
during successive generations, exchanging conformational parameters, and 
competing in a similar way to biological evolution. Finally, the individuals with 
the lowest binding energy are selected (Morris et al. 1998). The minima are then 
passed to later generations. 
 
AutoDock4 possesses also a simulated annealing search method as well as a 
traditional algorithm search. Conversely, the empirical free energy force field is 
based on a thermodynamic model that includes the intramolecular energies into 
the predicted binding energy. This force field evaluates both bound and unbound 
energy states and is used to predict binding free energies of molecules. It makes 
use of a charge based desolvation method which is calibrated using a set of 188 
protein-ligand complexes for all of which the structure and binding energy is 
known. For this set, studies have shown a standard error of 2-3 Kcal/mol in the 
prediction of binding free energy (Morris et al. 2009). Compared to AutoDock4, 
AutoDock Vina shares some concepts and approaches, such as the pre-
calculation of grid maps - in Vina this happens internally - the idea of docking as 
a stochastic optimisation of the scoring function, the structure format (PDBQT) 
and various implementation characteristics, such as pre-calculating the 
interaction between every atom pair at each distance. AutoDock Vina has an 





global optimizer) to provide docking conformations and is able to take 















2.  Methodology 
2.1 Bioinformatics docking studies, molecular and homology modelling  
2.1.1 Homology modelling 
The ligand binding domains (LBD) of human ERα and ERβ have been well 
described. These were utilised as templates for homology modelling 
experiments using X-ray crystallography data retrieved from the protein data 
bank (RCSB) and using the on-line SWISS-MODEL server (Biasini et al. 2014). 
The PDB files for the experimental crystal structures (coordinates for the 
templates) were uploaded in the oligomeric form without ligands and in the 
absence of non-amino acid groups. The input data used was the LBD sequence 
for ERα and ERβ, accession numbers P03372 and Q92731 respectively and 
submitted in FASTA format.   
 
Homology models of the 3D-structure of ERs were constructed using the amino 
acid sequences for different human ER subtypes and variants retrieved from 
UNIPROT (Appendix 1, table 4), in conjunction with the multiple sequence 
alignment program Cluster Omega (The European Bioinformatics Institute 
EMBL-EBI, 2017) to identify the LBDs (Appendix 1, table 4).  The quality of the 
structures built were evaluated using the workspace at SWISS-MODEL and 
were assessed using the quaternary structure coordinates of the template 
QMEAN. The model structures were further validated and assessed using the 
SWISS-MODEL server tools – the global and per residue model quality was 





quality was evaluated using Anolea (Melo and Feytmans 1998) and 
Ramachandran plots (Uchoa et al. 2004) to analyse the protein structure and 
the quality of the model  (Laskowski et al. 1993).  
 
2.1.2 Ligand selection 
A range of potential/known ER binding ligands were evaluated in this study. 
These included naturally-occurring (endogenous), synthetic (drug) and 
exogenous (dietary) compounds with agonist/antagonist ER binding properties. 
The SMILES codes for the ligands were downloaded from the phenol database 
(http://phenol-explorer.eu) and input structures were generated by Open Babel  
(O’Boyle et al. 2011) and Cactus software (http://cactus.nci.nih.gov/translate/) 
and from Zinc docking database alongside those generated using Open Babel. 
The structure of the ligands estradiol (ER agonist) and 4-hydroxyTamoxifen (ER 
antagonist) were obtained from the X-ray crystallography data available at the 
PDB databank described above. These were compared with the ligand 
structures produced and retrieved ligand structures from downloaded in silico 
experiments. The ligand structures were not subjected to energy minimisation 
as the docking software used in downstream experiments accommodates this. 
 
2.1.3 Locating ligand binding site(s) 
The ligand binding sites were predicted using the meta-server approach to 
protein-ligand binding site prediction COACH (Consensus approach TM-SITE 
and S-SITE with other structure-based programs) (Yang, Roy, and Zhang 2013) 
which utilises two comparative methods: specific substructure binding 





combining with other structure based software to generate a consensus of the 
possible binding sites for a given ligand and enabling the optimal coordinates to 
be localised for the grid box for the docking experiments.    
 
2.1.4 Protein, ligand input file preparation and grid parameters 
Docking experiments utilised PDBQT files for both ligand and receptor. The 
ligand file encodes a torsion tree and both files display hydrogen atoms, partial 
charges and non-polar hydrogen merged.  
 
For the macromolecule preparation; firstly, all hydrogen atoms were removed, 
then polar hydrogen atoms were added and restored from the ERs PDB files. 
The AutoDock tool (ADT) function was used to check for the net charge of the 
macromolecule and Gasteiger charges were added to each atom, the files were 
then saved as PDBQT files. For ligand preparation, hydrogen atoms (polar and 
non-polar) were added, ADT was used to compute the Gasteiger charges, 
calculate and define the rotatable bonds and to estimate the number of torsional 
degrees of freedom, again, the files were saved in the PDBQT format. 
 
For AutoDock Vina docking it was necessary to define the centre coordinates x, 
y, z and the sizes of the molecules of the grid location in the PDB file (File 
containing atomic coordinates. The coordinates were obtained using the “Grid 
Widget” in ADT, a three dimensional box was created whereby the binding 
pocket was located, obtained by literature review and by PBD ER-LBD files and 





space of the ligand binding pocket but ensuring sufficient room for free-
movement of the ligand. For convenience some command line options were 
written in a configuration file.  
      
2.1.5 Computer simulated ligand binding  
AutoDock Vina was used as the docking software (Trott and Olson 2010a) and 
was run from the command prompt in a default directory; all the files 
(receptor.pdbqt, ligand.pdbqt, configuration.txt) were saved in the same folder. 
The command was “\vina.exe --config configuration.txt –log ligand.txt, and two 
additional files were generated one with the docking coordinates and a txt file 
with output. Data generated by the software was analysed based on the binding 




















3. ERα and ERβ in breast cancer 
3.1 Introduction  
Receptors for 17β-estradiol (estradiol) are present in many cell types and are 
found on the epithelial cell membranes of the breast (in the form of G-protein 
coupled receptors) and in the intracellular space where they function as nuclear 
receptors (Kurokawa et al. 1995). In breast cancer (BC) most of our 
understanding of ER relates to the function of the intracellular receptors ERα 
and ERβ. The downstream molecular components activated following the 
dimerization of ERα and ERβ play an important role in BC development and 
disease progression (Palmieri et al. 2002). Elucidation of the biological role of 
ER has led to the development of important classes of drugs that prevent the 
normal function of estradiol, blocking BC cell proliferation through the ER. Drugs 
acting as estrogen antagonists such as Tamoxifen have led to significant 
improvements in patient survival, for example as shown in the large studies 
undertaken by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG, 
2017).  The success of anti-estrogen drugs illustrates the importance of 
strategies aimed at targeting the ER as both anti-BC (preventative) as well as 
treatment modalities (Furr and Jordan 1984; Howell 2006; Jiang, Zheng, and 
Wang 2013).   
 
As described in Chapter 1, ERs are involved in complex pathways as a result of 
the binding of endogenously produced estradiol.  In addition, exogenous 





wide range of outcomes in terms of the ER related signalling pathways and 
transcription events that are affected.  
 
ERα and ERβ (Fixemer et al. 2003) are encoded on different chromosomes by 
the ESR1 and ESR2 genes respectively (Barnes, 2010). ERα and ERβ show 
structural similarities and their affinity to estradiol is similar for both the wild type 
and subtypes of the receptors. However, each ER type displays a different 
profile in terms of the pathways that are activated (Marino et al. 2006). Further 
complexity arises as ERα and ERβ can be co-expressed and may act as 
homodimers or heterodimers. Variants in both ERα and ERβ have been 
described.  
 
ERβ is an important mediator of estradiol action in BC and has been shown to 
be co-expressed with ERα (Green et al. 1986; Mosselman, Polman, and 
Dijkema 1996) but currently it is only ERα that is used for the classification of 
ER status in BC. There remains the potential to classify BC according to both 
ERα and ERβ status and the ERβ receptor may also be a novel drug target in 
BC. Further knowledge of ERβ biology may result in an improved understanding 
of BC biology, prognosis and potentially lead to new approaches to BC 
treatment. 
 
Computational methods for protein structure prediction and ligand binding 
interaction are widely used in drug discovery programmes. Modelling 3-D 





prerequisite for the study of protein dynamics and interactions with ligands and 
offers the potential for screening large numbers of compounds in silico (Schmidt, 
Bergner, and Schwede 2014). Information related to the spatial arrangement of 
amino acids and consequent protein structure allows the design of further 
experiments around ligand-receptor interactions, for example ligand docking. 
Methods for prediction of protein structure such as homology modelling are 
frequently used as they overcome the need for direct work with proteins and the 
associated obstacles that occur related to gene cloning, protein expression and 
purification and also circumvent issues around protein crystallisation. Homology 
modelling does, however, rely on high quality crystal structures of proteins from 
the same family and with similar amino acids sequences, similar structures and 
folds (Schmidt et al. 2014) to use as templates in order to generate reliable 


















The aim of the work described in this chapter was to identify the ERα and ERβ 
ligand binding domain (LBD) and assess the use of this as a template for 
homology modelling studies with ER binding drugs Tamoxifen and Fulvestrant. 
In order to achieve these aims, the following objectives were considered:  
3.2.1 Objectives  
• Selection of human ERα and ERβ crystal structures from the PDB 
database, determining the most representative structure for agonist and 
antagonist conformations. 
• Building a 3-D homology model and validation of the LBD for wild type 
ERα and ERβ. 
• In silico docking of wild type ERα and ERβ with different ligands (E1, E2, 












3.3 Results  
3.3.1 Homology modelling  
The homology modelling was based on structures that had been identified using 
the sequences of the canonical forms of ERs retrieved from Universal Protein 
Resource (Uniprot) in FASTA format (ERα accession number P03372, ERβ 
accession number Q92731). This study investigated the ligand binding domain 
(LBD) of the ERα and ERβ receptors. The following criteria were used for the 
selection:  
• Structures where the ER had been evaluated as a complex with a range 
of exogenous and endogenous ligands. 
• Structures with the highest possible resolution - to ensure high quality X-
ray crystallography based structures. 
• Avoidance of crystal structures showing mutations - in order to avoid 
possible aberrant conformations. 
301 structures of the human estrogen receptor are available in the Research 
Collaboratory for Structural Bioinformatics (RCSB), only 94 displayed a 
reasonable good resolution (under 2.5 Å). The top ten structures with the best 
resolution and only in complex with one of the ligands (estradiol and Tamoxifen) 
were selected. After the structures with mutations were excluded as well, 3D 
structures were retrieved from the PDB database, RCSB protein database (URL 
www.rcsb.org) (Berman et al. 2000) as shown in below: 
ERα agonist   PDB ID: 1GWR; 2.4 Å (Warnmark et al. 2002) 
ERα antagonist PDB ID: 3ERT; 1.9 Å (Shiau et al. 1998) 
ERβ agonist   PDB ID: 2J7X; 2.1 Å (Pike et al, unpublished) 






3.3.1.1 Wild type ERα 
The homology model for wild type human ERα produced using PYMOL and 




Figure 3. ERα (ESR1) ligand binding domain. On the left, structure of human 
wild type ERα ligand-binding domain homodimer complexed with estradiol taken 
from the PDB database (based on PyMOL rendering of PDB 1GWR). On the 
right, zoom view of the ERα/estradiol complex: showing key amino acid residues 
(GLU-353, ARG-394, PHE-404 and HIS-524) in the binding pocket that interact 
with estradiol when complexed with ERα. 
 
 
Previous studies have described two key domains in the structures of the ER 
proteins, the ligand binding and the DNA binding domains.  In this study the LBD 
was chosen for the structure-based studies and used as a template for the 
homology modelling process.  The key interactions between the amino acid 
backbone and the ligand(s) were analysed using Pymol version 1.7.4 






For ERα wild type 3D structures (PDB IDs: 1GWR estradiol/ERα, 1X7R 
Genistein/ERα and 3ERT 4-OHT/ERα) and for ERβ wild type (PDB IDs: 4J24 
estradiol/ERβ, 1QKM Genistein/ERβ and 2FSZ OHT/ERβ) were retrieved from 
the protein database. The PDB files were used in the different stages of the 
structure-based study. Multimeric complexes were reduced to the single amino 
acid chain structures from the corresponding PDB files using the MGL tool as 











Figure 4. ERα (ESR1) ligand binding domain (LBD) homology model 
(SWISS-MODEL) showing the amino acid residues that interact with 
estradiol, recapitulating the information shown in figure 3. On left: cartoon 
cylindrical helix representation (helices 1 to 12).In the centre, LBD shown in 
cartoon cylindrical helix (cyan) representation and estradiol (red stick) and on 





























Figure 5. ERα (ESR1) ligand binding domain homology model (SWISS-
MODEL). Top left hand, predicted ligand binding pocket in complex with 
estradiol based on analysis using the RaptorX binding prediction server, the 
highest scoring residues predicted to lie within the binding site for sequence 
segment [1, 252]:1): M42 L45 A49 E52 L83 L86 M87 L90 R93 F103 M120 I123 
G220 H223 L224 Possible ligands: EST, OHT. Top right hand, surface 
representation of wild type ERα LBD in complex with estradiol (red). Lower 
panel: 2D layout of the key amino acids in the ligand binding pocket that retain 
estradiol. 
 
Identification of the LBD is an important aim for structure-based studies and 
docking experiments but in silico approaches may be inaccurate in this regard. 





example, by adopting specific structure comparisons and sequence alignment 
through the use of the meta-server COACH (Yang et al. 2013).  
 
In this approach, coordinates for the amino acids described by the binding site 
prediction meta-server were identified enabling generation of an accurate grid 
box for use in the AutoDock Vina system (Trott and Olson 2010b). The LBD was 
identified by multiple sequence alignment using CLUSTAL-OMEGA (EMBL-EBI 
2013) and quality of the models assessed by the SWISS-MODEL server Qmean 
Z-score providing data about the absolute quality of the predicted homology 
models (Figure 5). 







3.3.1.2 Wild type ERβ 
Wild type human ERβ is smaller than ERα but they show a high homology in 
the DNA binding domain (96 %). However, the structures are only 57% similar 
at the LBD (ERα amino acid residues 302 to 552 and 255 to 504 in ERβ (Kuiper 
et al. 1996). Whilst many of the studies undertaken with ER in BC have focussed 
on ERα, the ERβ has been reported to be an important partner acting as a 
homodimer and heterodimer with ERα (Cowley et al. 1997).  
 
In this study, wild type ERβ was evaluated using PYMOL, basing the PYMOL 










Figure 6. ERβ (ESR2) ligand binding domain. On the left, structure of the 
human wild type ERβ ligand binding domain in complex with estradiol taken 
from the PDB database (based on PyMOL rendering of PDB 4J24). On the 







Although the crystal structure of wild type ERs rendered using PyMol (as shown 
above) are often used as targets in the next step of the work flow for in silico 
experiments, the approach taken here was to use the SWISS-MODEL server 
and produce a new model enabling the PyMol rendered and the SWISS-MODEL 


















Figure 7. ERβ (ESR2) ligand binding domain (LBD) homology model 
(SWISS-MODEL). Upper left: cartoon showing cylindrical helix representation 
(helices 1 to 12). Upper right: zoom view of upper left showing the LBD in 
cartoon with cylindrical helices and estradiol (red stick representation) and helix 
number indicated (black). Lower panel: ERβ surface structure (blue) and 
estradiol (red) in the ligand binding site. After, re-docking the ligand (E2) 





The ERs have been widely studied and although the binding pocket has been 
described for many endogenous ligands and drugs it has been less well studied 
in terms of the binding of other compounds for example those with either agonist 
or antagonist binding properties found in the diet or the environment. The in 
silico methods described and utilised here enabled investigation of the amino 
acids in the binding pocket of the ER and the availability of these coordinates 
allowed the ER to be investigated using other in silico structure based studies 






















 Figure 8. Sequence alignment ERα and ERβ. Residues that belong to helices 
in the ERα are framed by a black rectangle (Number of the helices are provided 
in the top of each one in instance H1, H2 and so on) in yellow boxes are the key 
estradiol binding residues in ERα (M42 L45 A49 E52 L83 L86 M87 L90 R93 
F103 M120 I123 G220 H223 L224) and in blue for ERβ (M81 L84 L87 A88 E91 
L125 M126 L129 R132 F142 I162 G258 H261 L262). Identifying these residues 
provides an understanding of the “grid” or “space” needed for investigation of 
other ligands in later docking studies. Each receptor was run twice in the multiple 
alignment one with the respective residue number in the full length protein 

















































































































































































































































































































































3.3.2 Physiological and antagonist ligands for ERα and ERβ 
This study was concerned with the comparative docking of three endogenous 
estrogens and two anti-breast cancer drugs.  
 
To undertake this study it was necessary to evaluate the ER structures built in 
silico and their predicted ER binding sites, calculated spatial position of the 
ligand and amino acid environment needed for successful docking of these 
agonist and antagonist structures.   
 
The ligand structures were downloaded from the zinc docking database 
(http://zinc.docking.org) and input structures were generated using Open Babel 
(O’Boyle et al. 2011). Energy minimization was performed for each of the ligand 
structures in turn as the next (docking) step using AutoDock Vina was known to 
apply partial atomic charges.  
 
As can be seen in Table 1, one of the key differences between the ER agonists 
(estradiol, estrone, and estriol) and antagonists (Tamoxifen, Fulvestrant) is their 
molecular size. The agonists were of a lower molecular weight compared with 
the antagonists which exhibited a more bulky structure accompanied by larger 






Table 1. ER ligands. In the Simplified Molecular-Input Line-Entry system 
(SMILE) code strings.  2D and 3D structures were produced using the Open 
Babel software(O'Boyle et al 2011); the molecular mass was obtained from the 
ChemSpider database (http://www.chemspider.com). 
 
























































Figure 10. Comparison of the results of docking estradiol to ERα (ESR1) 
with the crystal structure of ERα: estradiol complex. Upper left: 2D 
representation of binding pocket with estradiol based on the crystal structure 
(taken from the PDB database PDB ID: 1GWR). Upper right: 2D representation 
of binding pocket and estradiol based on the AutoDock Vina pose. In green the 
ligand in the binding pocket from the crystallography, in red the ligand in the 





binding pocket and ligand based on the pose from the AutoDock Vina showing 
the lowest binding energy (-10.9 Kcal/mol). 
The model developed for estradiol binding to ERα using the docking approach 
with AutoDock Vina, above, closely recapitulated the X-ray crystallography 
experiments. In silico experiments were run with AutoDock Vina three times to 
compare consistency of the data, each time the exhaustiveness or number of 
runs were set up by default (10) models were also developed for estrone and 
estriol binding and these are shown in Appendix 2 Figure 3 and 4 . 
 
Ligand-binding interactions in ERα-estradiol complex show GLU353 aa and 
HIS524 forming hydrogen bonds in both sides of the ligand with the hydroxyl 
group and ARG394 support the location of GLU353 and PHE404 (Tanenbaum 
et al. 1998) . It was clear from this analysis that molecules of larger molecular 
sizes would not be accommodated in the ligand binding site (as agonists). 
Accordingly, a second template model was produced to enable the interaction 
between antagonists and the ER to be evaluated. In this approach, again, the 
crystal structure of ERα in complex with 4-hydroxyTamoxifen was taken and 
used as the template for the homology modelling as shown in Figure 11. 
 
4-hydroxyTamoxifen (Figure 11) and Fulvestrant interact with ERα binding to a 
larger groove compared with the interaction between the agonists, for example 
estradiol (Figure 7), estrone and estriol (Appendix 2, figure 3 and 4).  The 
following amino acids of the ERα receptor backbone anchored both 4-
Hydroxytamoxifen and Fulvestrant in the same place as estradiol; GLU353 and 





repeated using ERβ as shown in Appendix 2 (figure 20), ARG346 and GLU305 
play the same role as in its homologous part in the ERα (ARG394, GLUE353 
and ARG394) forming hydrogen bonds with the Tamoxifen. 
 
 
Figure 11. 4-hydroxyTamoxifen binding to ERα.  On the left: 2D 
representation of binding pocket and ligand reported from crystallography 
experiments (taken from PDB database 3ERT). On the right: 2D representation 
of binding pocket and ligand based on the AutoDock Vina pose. Lower panel: 
cartoon representation of the amino acid interactions, in green the ligand from 
the crystallography, in the red the ligand in the pose produced by AutoDock Vina 






3.4 Discussion  
Over the last three decades different computational approaches have been 
adopted as prediction methods for in silico evaluation of receptor-ligand 
interactions (Schmidt et al. 2014). The methods developed have become 
increasingly complex necessitating a greater number of permutations and 
combinations of variables to be assessed in the computational space pre-
calculating the interaction of each atom type Vina uses an united-atom scoring 
function (only heavy atoms) also Vina does not take into account partial charges 
since internally it uses electrostatic interactions (Trott and Olson 2010b). 
Computer processing power has vastly improved and modelling/docking 
approaches may now be undertaken by applications that utilise either single 
desktop computers or by access to clusters or computer-grids (Forli et al. 2016).  
As a result of these improved methods we have now reached the point whereby 
reliable models can be produced and used for in silico experiments of receptor-
ligand interactions (Trott and Olson 2010b), such as has been used here for the 
wild type forms of monomeric ERα and ERβ. The fact that we pre-calculated the 
binding site helped to reduce the grid size making it easier for the docking 
program to explore it.  
 
In this study the in silico modelling of wild type ERα and ERβ was first attempted 
using the full length protein (data not shown), this proved unsuccessful due to 
the length and complexity of the full length structure and the absence of an X-
ray crystallography-derived template. Homology modelling was then performed 





LBD (human wild type ERα and ERβ in E. coli based expression systems); the 
arrangement of the α-helices was very similar both in terms of the number of 
helices and their position/orientation. Importantly α helix 12 which has been 
reported to extend away from the monomer and on ligand-binding has been 
shown to interact with the partner monomer to stabilise homodimeric and 
heterodimeric forms of ER and was found to adopt a similar configuration in the 
homology models produced here. 
 
When the docking of agonists was considered using AutoDock Vina the key 
amino acids were found orientating and positioning estradiol in the binding 
pocket. Tanenbaum et al. (1998) have described the crystal structure of the LBD 
of human ERα and highlighted the importance of the following amino acid 
residues: Glu-353 for anchoring the 3-hydroxyl group of estradiol and its 
analogues (in contrast to the 3-keto group found in other steroid hormones); the 
“bracing” of the side chain of Arg-394 by a hydrogen bond to the carbonyl 
residue of the amino acid preceding Phe-404; the presence of hydrogen 
bonding between the 17-OH of estradiol and His-524. These four key amino 
acids were all observed at the correct positions with respect to estradiol in the 
binding pocket following the AutoDock Vina experiments though in this case the 
binding site can be pre-calculated due to the extensive research into the 
receptor with AutoDock Vina which has displayed good performance with a 






The binding of the anti-breast cancer drug 4-Hydroxytamoxifen to human ER 
has also been evaluated. This important antagonist functions by preventing 
estradiol occupying the LBD of ER and giving rise to a conformational change 
on the surface of the ER hindering the interaction of co-activator peptides, such 
as the NR-box II peptide (Shiau et al. 1998). The orientation and anchoring of 
4-Hydroxytamoxifen following the docking experiment with AutoDock Vina is 
shown as an overlay in Figure 11 illustrates the success of this approach.   
 
As it was not possible to model the full length receptor, potential interference by 
other domains of the ER, e.g. the DNA binding domain, activation factor domain, 
etc., with respect to agonist and antagonist binding this remains an area for 
further future exploration. It is important to note, however, that this consideration 
also applies to data from the X-ray crystallography based experiments with 
these receptors as well. Despite the inherent shortcomings associated with 
studying the human ERα and ERβ LBD alone, the system described here 
recapitulated the important amino acid residues of the LBD with ligand poses 
and interactions commensurate with those reported for both the agonists and 
the antagonists of ERα and ERβ in the X-ray crystallography experiments.  
 
The next phase of this work sought to use these homology models to study the 








4. In silico docking experiments with phytoestrogens and wild 
type human ERα and ERβ LBD 
 
4.1 Introduction 
The variation in breast cancer incidence and survival across the globe has led 
to an interest in the potential protective effect of dietary phytoestrogens, 
particularly as countries where the diet is enriched in phytoestrogens have lower 
breast cancer incidence and greater survival rates. Phytoestrogens are found in 
the greatest abundance in soya products and other legumes (Mazur 1998), 
seeds, whole-grains, fruit, vegetables and beverages (Kuhnle et al. 2008; 
Kuhnle et al. 2009) and are classified into two main groups: isoflavones and 
lignans. Meta-analyses have reported a decreased breast cancer risk with 
increased lignan and isoflavone exposure in Asian but not in Western 
populations (Buck et al. 2010; Dong and Qin 2011; Wu et al. 2008). 
 
Phytoestrogens elicit a multitude of effects in vivo acting as naturally-occurring 
selective ER modulators via their ER binding properties (Mueller et al. 2004). 
The pharmacokinetic properties of these compounds have led to concerns that 
increased exposure to dietary phytoestrogens might promote breast cancer 
recurrence and/or affect the efficacy of hormone therapies. At present, studies 
concerned with unravelling the effect of phytoestrogens have shown that they 
can  reduce tyrosine kinase activity (Akiyama et al. 1987), inhibit signalling 





2012), angiogenesis (Farina et al. 2006), cellular invasion and metastasis (Shao 
et al. 1998). However, a placebo-controlled study of breast cancer patients 
(n=114) randomised to soy-protein consumption (over a 7-30 day period) 
followed by tumour tissue genome-wide expression analysis reported an 
increase in the expression level of mRNA for genes associated with cellular 
proliferation (Shike et al. 2014), exposure of the MCF7 breast cancer cell line to 
the isoflavone daidzein increased the expression levels of transcription factors 
(Koo et al. 2015) and in a murine model increased isoflavone exposure resulted 
in an increase in the formation of lung metastases (Yang et al. 2015).  
 
In the last two decades, a number of databases have been established 
containing considerable information about dietary polyphenols (Pasinetti et al. 
2017)(Schweartz et al, 2009). One of the largest databases is Phenol-Explorer 
(http://phenol-explorer.eu/) (Rothwell et al. 2012).  This resource contains 
information related to the polyphenol content in foods with >35,000 content 
values of 500 different polyphenols in >400 foods, derived from >1300 peer 
reviewed publications. Within the database are polyphenols with estrogen-like 
structures, they have been classified into either the isoflavone or lignan 
groupings.  
 
One of the main concerns around phytoestrogen consumption by breast cancer 
patients is the potential for interference with the binding of Tamoxifen (and other 
drugs) to ER. A further consideration is whether known splice variants in the ER 





or endogenous estrogens such as dietary phytoestrogens or endogenous 
ligands such as estradiol to the ER. 
 
The DietCompLyf study is a multicentre prospective cohort study investigating 
diet, lifestyle and complementary therapy use of UK breast cancer patients. It is 
the most comprehensive UK-based study concerned with diet and breast cancer 
progression to date and includes 3144 breast cancer patients with >5 year follow 
up data. The study is being coordinated within the Department of Biomedical 
Sciences and is concerned with effects of the isoflavones genistein, daidzein, 
glycitein, biochanin A and formononetin, and the lignans secoisolariciresinol, 
matairesinol, shonanin, and their metabolites enterodiol, enterolactone and 
equol on breast cancer progression. Formononetin and biochanin A are methyl 
forms of isoflavones that are often found in dietary supplements and these can 
be metabolised to daidzein and genistein, Daidzein itself can also be 
metabolised to O-desmethylangolensin (ODMA) and to equol by the intestinal 
microbiome.  
 
To evaluate the potential role of these dietary chemicals with respect to breast 
cancer aetiology, the binding properties of these phytoestrogens to the LBD of 
ERα and ERβ was assessed using the homology models developed as 









The aim of the work described in this chapter was to develop and analyse, in 
silico, the interaction between dietary phytoestrogens (assessed in the 
DietCompLyf study) and the LBD of wild type human ERα and ERβ. A 
secondary aim was to develop homology models of the LBD of variants in ERα 
and ERβ for later studies with these structures.  
4.2.1 Objectives  
• To rank the binding properties of dietary phytoestrogens to the binding 
of Tamoxifen and endogenous ligands to the LBD of ERα and ERβ. 














4.3 Results  
4.3.1 Phytoestrogen ligands for ERα and ERβ 
This study was concerned with the comparative docking of dietary 
phytoestrogens, endogenous estrogens and two anti-breast cancer drugs 
(Tamoxifen and Fulvestrant). The ER structures built in silico (Chapter 3) were 
used. The SMILES codes for the phytoestrogens investigated in this study were 
downloaded from the phenol-explorer database described above (http://phenol-
explorer.eu).  Each of the input structures were generated by the use of the 
Open Babel (O’Boyle et al. 2011) and Cactus software 
(http://cactus.nci.nih.gov/translate/) as before. The phytoestrogens considered 




















































Table 2a continued. Phytoestrogens under investigation in this study. 
















































Phytoestrogens are a group of heterogeneous plant-derived compounds many 
of which are thought to be endocrine disruptors. This diverse group includes 
chemicals with structural similarity to estradiol, Chapter 3, Table 1, but 
additionally comprises chemicals containing both di- and tri-phenolic rings, 
Table 2. 
 
The only structures deposited in the PDB database pertaining to the human ER 
and dietary phytoestrogens were complexes of ER-genistein. Indeed, of the 
approximately 250 X-ray crystallography/NMR structures of human ER 
deposited in the PDB database only six are concerned with phytoestrogens and 
these focus on the interaction between ER and genistein. This is rather 
unsurprising as genistein is found in the greatest abundance of all the dietary 
phytoestrogens and is found in particular in  soy products and is an important 
dietary constituent for populations in the Far East (Lu and Anderson 1998). The 
crystal structure for genistein in complex with ERβ LBD, PDB ID: 1QKM (Pike 
et al. 1999) was been solved at 1.8 Å. In addition, the ER-genistein complex in 
conjunction with the NR box peptide has also been reported (ERα PDB ID: 
1X7R, 2.0 Å; ERβ PDB ID: 1X7J, 2.3 Å) (Manas et al. 2004). The X-ray 
crystallography work described genistein as interacting with the hormone 
binding pocket of ERβ altering the conformation of helix-12 (Chapter 3).  Upon 
genistein binding to ERβ, helix-12 no longer adopts the typical position observed 
when an agonist (for example estradiol) is bound but rather helix-12 becomes 






In this study the interaction between genistein and the LBD of ERα was 
determined using the approach described in Chapter 3.  The template used was 
ERα PBD ID: IGWR.  Subsequently, the phytoestrogens shown in Table 2 were 
evaluated with respect to the docking into the LBD. For genistein, and as 
described in the X-ray crystallography (Figure 12), in this model system, the OH- 
of the phenolic ring was found to interact with the side chains of the amino acids 
Glu-353 and Arg-394, both of these residues were correctly positioned following 
the AutoDock Vina experiments. Similarly, the –OH of E2 showed the correct 
conformation - consistent with the formation of a hydrogen bond between the –
OH and His-524 at the “distal end” of the binding pocket.   
 
Figure 12. Genistein binding to ERα, on the left 2D representation of binding 
pocket and ligand. On the right cartoon representation of the amino acid 
interactions. Model template based on agonist conformation (PDB ID: 1GWR 








Figure 13. Daidzein binding ERα. On the left 2D representation of binding 
pocket and ligand. On the right cartoon representation of the amino acid 
interactions. Model template based on agonist conformation (PDB ID: 1GWR 





Figure 14. O-desmethylangolensin (ODMA) binding ERα. On the left 2D 
representation of binding pocket and ligand. On the right cartoon representation 
of the amino acid interactions. Model template based on agonist conformation 
(PDB ID: 1GWR Chain A) and the red ligand is the pose produced by AutoDock 






Figure 15. Enterolactone binding ERα. On the left 2D representation of 
binding pocket and ligand. On the right cartoon representation of the amino acid 
interactions. Model template based on agonist conformation (PDB ID: 1GWR 
Chain A) and the red ligand is the pose produced by AutoDock Vina at the lowest 
binding energy. 
 
All of the phytoestrogens studied using AutoDock Vina interacted with the 
hormone binding site of ERα as shown in Figures 12 to 15 and Table 3. The 
LBD is characterised by the presence of hydrophobic amino acids, favouring the 
interaction with the (hydrophobic) bi- and tri-phenolic ring structures that are a 
feature of the phytoestrogens studied.  Genistein, daidzein and ODMA show 
considerable structural similarity and, as would be predicted, behaved similarly: 
interacting with Glu-353 and Arg-354 in the LBD. His-524 was also consistently 
found within the binding sites anchoring the phytoestrogens as shown in the 
previous figure 12 and 14. As the LBD for wild type ERα and ERβ also show 
structural similarities (Chapter 3) (Moras and Gronemeyer 1998) the 
observations regarding phytoestrogen interactions with ERα were expected to 
be very similar for ERβ - evaluation of the free energy of binding, a measure of 






4.3.2 The affinity of endogenous estrogens, drugs and dietary 
phytoestrogens to the LBD of ERα and ERβ  
AutoDock Vina is a highly sophisticated computational system (Chapter 1) with 
in-built scoring functions, for example, the root-mean square deviation (RMSD) 
score and estimations for the change in free energy (∆G) and predicted free 
energies of binding (kcal/mol) for ligand-receptor interactions.  The AutoDock 
Vina free energy measurement tool was used to rank the affinity of interaction 
of estrogens, drugs and phytoestrogens to ERα and ERβ as shown in Table 3.  
Table 3. Affinity of estrogen and phytoestrogens to wild type ERα and ERβ 
LBD. The computational docking program AutoDock Vina provided free energy 
values. The compounds have been listed in order of ranking with highest affinity 
interactions shown at the top of the list for each class of compounds. Seco = 
secoisolariciresinol. ODMA = O-desmethylangolensin. 








Estradiol -10.6 -10.7 
Estrone -10.2 -10.4 
Estriol -7.4 -10 
Drugs 
  
Fulvestrant -7.1 -6.4 






Genistein -8.7 -8.3 
Daidzein -8.5 -8.4 
Naringenin -8.1 -8.2 
Biochanin -7.9 -6.6 
Formononetin -7.6 -7.1 
Glycitein -7.3 -6.5 
Lignans 
  
Shonanin -7.9 -6.7 
Seco -7.2 -5.9  




Enterolactone -9.1 -8.6 
ODMA -8.3 -8.5 
Equol -7.2 -8.5 
 







In systems such as AutoDock Vina, the free-energy binding calculation is used 
to rank the ligands with the greatest affinity to the receptor. This value will be 
influenced by a range of factors including the resolution of the X-ray crystal 
structure used as the template. The highest affinity interactions with the LBD of 
ERα and ERβ calculated by the AutoDock Vina system were for the estrogens 
(estradiol, estrone, and estriol). In addition, the isoflavones genistein, daidzein, 
and metabolites enterolactone, equol and ODMA all showed greater affinity to 
the receptor than the lignans secoisolariciresinol, matairesinol and shonanin 
with binding energies for these phytoestrogens similar or greater than for 
Tamoxifen. Further work was undertaken to determine whether the 
phytoestrogens described above interact with the ER as antagonists (Chapter 
5) and to assess the potential binding of phytoestrogens to known variants of 
the ER (Chapter 1).  As a pre-requisite for this work, homology models of the 
variants reported for ERα and ERβ were prepared. A multi-sequence alignment 
was undertaken using Clustal-Omega with the amino acid sequences for the 
LBDs for ERα and ERβ as shown in Figure 16. Four variants have been 
described for ERα (including the wild type, canonical sequence, isoform 1).  ERα 
isoform 2 has a large part of the LBD deleted from amino acids 255-366 (shown 
in Figure 16 as residues 1-65); isoform 3 has precisely the same LBD as the 
wild type sequence; isoform 4 comprises a shorter LBD of only 184 amino acids 
exhibiting significant changes to the LBD alterations/deletions in amino acids 
458-595 (shown in Figure 16 as residues 157-252). In addition, isoforms 3 and 








































































































































































































































































In contrast to ERα, nine variants have been described for ERβ (including the 
wild type, canonical sequence, isoform 1), Figure 17. ERβ isoform 2 has a large 
part of the LBD deleted from amino acids 469-530 (shown in Figure 17 as 
residues 173-204); isoform 3 has premature stop codon in the mRNA the result 
of which is it is unlikely to be translated into a mature protein, isoforms 4, 5 and 
6 show similarity in the LBD until changes which occur in amino acids 469-530 
(shown in Figure 17 as residues 174 onwards). These changes in isoforms 5 
and 6 mean that they will not be able to form homodimers  (Bairoch et al. 2005).  
 
Isoform 7 is missing amino acids 319-409 (shown in Figure 17 as residues 2-
94); isoform 8 is missing amino acids 376-530 (shown in Figure 17 as residues 
77 onwards) and displays 365-375: DEGKCVEGILE→YVPSGHSDPGC; finally; 
isoform 9 is missing amino acids 475-530 (shown in Figure 17 as residues 174 
onwards) and displays 469-474: SNKGME→RSCVYK. 
 
4.3.3 Homology modelling of the ERα and ERβ isoforms 
The amino acid sequences for isoforms of ERα and ERβ presented in Figures 
16 and 17 were used in homology modelling experiments performed in the 
SWISS-MODEL workspace, Table 4. The quality of the models produced was 
assessed using the “global quality of the model” (GQME QMEAN4) scoring 































































































































































Table 4. Homology models of different isoforms of ERα/ERβ LBD. The 
homology modelling and model quality evaluation was performed in the SWISS-
MODEL workspace. Global quality of the model was scored using the GQME-
QMEAN4 system. GQME estimates the accuracy of the model according to the 
target template alignment, while QMEAN scores local geometry and distance-
dependent potentials to assess possible ligand-receptor interactions. 
PROTEIN NAME MODEL 
 
ERα (ESR1) Isoform 2  
Template PDB ID 1GWR, Chain A 
GQME 0.99 
Qmean4 -1.33  
Template Resolution 2.40 Å  
 
ERα (ESR1) Isoform 4 
Template PDB ID 1GWR, Chain A 
GQME 0.96 
Qmean4 -1.35 
Template Resolution 2.40 Å 
  
 
ERβ (ESR2) Isoform 2 
Template PDB ID 4J24  Chain A 
GQME 0.81 
Qmean4 -1.55 
Template Resolution 2.10 Å  
ERβ (ESR2) Isoform  4 
Template PDB ID 4J24  Chain A 
GQME 0.79 
Qmean4 -1.12 






Table 4a continued. Homology models of different isoforms of ERα/ERβ 
LBD. 
 
PROTEIN NAME MODEL 
ERβ (ESR2)  Isoform 5 
Template PDB ID 4J24  Chain A 
GQME 0.83 
Qmean4 -1.10 
Template Resolution 2.10 Å 
 
ERβ (ESR2) Isoform  6 
Template PDB ID 4J24  Chain A 
GQME 0.83 
Qmean4 -1.19 
Template Resolution 2.10 Å 
 
 
ERβ (ESR2) Isoform 7 
Template PDB ID 4J24  Chain A 
GQME 0.76 
Qmean4 -0.22 
Template Resolution 2.10 Å 
  
ERβ (ESR2) Isoform 9 
Template PDB ID 4J24  Chain A 
GQME 0.83 
Qmean4 -1.08 






The structures presented in Table 4, represent all the isoforms that were 
successfully modelled using the SWISS-MODEL system with estradiol in the 
LBD. Note, ERα isoform 3 is not shown as this has exactly the same sequence 
as the wild type receptor.  ERα isoform 2 and 4 were both found to bind estradiol 
despite the many missing amino acid residues from the LBD isoform 2 which is 
missing the first three helices physically opening the binding pocket in the 
structure, hence the number of residues that it can interact with are less; L42, 
L45, A49, E52 are not present in this structure hence lowering the predicted 
energy binding. Of the nine isoforms that have been described for ERβ isoforms 
2 and 5 were able to form homodimers.  Conversely, all the other isoforms that 
were modelled using this system remained in monomeric form using the same 















4.4 Discussion  
The improvements in breast cancer survival rates over the past two decades 
have led to an increased interest in the role of diet and lifestyle on breast cancer 
patient outcomes. Observational studies have reported a reduction in breast 
cancer mortality in post- but not in pre-menopausal women consuming the 
highest intakes of lignans (McCann et al. 2012) and reduced mortality overall, 
but not breast cancer-specific, for the highest quintile of the phytoestrogen 
metabolites, enterolactone and enterodiol (Buck et al. 2011).  Similarly, a recent 
meta-analysis described the association between enterolactone levels and 
reduced breast cancer specific mortality (Seibold et al. 2014). Despite these 
reports there is very limited information around the potential interaction between 
dietary phytoestrogens and their metabolites and the ER.  
 
The work presented in this chapter was concerned with the potential estrogenic 
activity of dietary phytoestrogens. The work extended the current understanding 
beyond the interaction between genistein (the isoflavone abundant in soy 
products) with the ER and showed the binding properties of both lignans as well 
as phytoestrogen metabolites. Most research on phytoestrogen enriched diets 
has been concerned with the effect of soy-based isoflavone consumption, 
however, lignans are the more widely consumed phytoestrogens of Western 
diets (Valsta et al. 2003).  The DietCompLyf study has reported that lignans are 
the main source of phytoestrogens in the diet of UK breast cancer patients and 
therefore it is of interest to consider the interaction between lignans and the ER 






Analysis of the docking data from the homology models produced using 
AutoDock Vina showed that estrogen and estrone bound to the LBD of ERα with 
the highest affinities (-10.6 and -10.7 Kcal/mol respectively) followed by ERβ 
binding (-7.4 and -10 Kcal/mol respectively).  Tamoxifen, as expected, bound 
weakly (ERα  -7.1 Kcal/mol and ERβ -6.4 Kcal/mol) in contrast the phytoestrogen 
metabolite enterolactone had an affinity for the ER slightly less than estradiol 
but greater than Tamoxifen (ERα -9.1 Kcal/mol and ERβ -8.6 Kcal/mol). In terms 
of the “ranking” of binding affinities, all of the dietary phytoestrogens showed 
lower affinity binding compared with estradiol this suggests that phytoestrogens 
should not displace estradiol from the LBD and therefore should not act as 
stimulatory compounds. It remains the case, however, that this observation will 
need to be tested in laboratory studies but this does support the findings of the 
epidemiological observational studies (Buck et al. 2011; McCann et al. 2012; 
Seibold et al. 2014) described above and suggesting that there is no 
disadvantage in terms of survival outcomes for breast cancer patients 
consuming phytoestrogens.    
 
The increasing interest in pharmacogenomics led to the preparation of in silico 
homology models of the isoforms for ER.  It may be the case that for some of 
the variants of the ER, phytoestrogen binding may be of a higher affinity and 
therefore may be potentially deleterious.  Some of the isoforms were observed 
to retain estradiol binding properties and were able to form homodimers. The 
next phase of this work, Chapter 5, is concerned with the binding of 
phytoestrogens to these isoforms and potential antagonistic properties of this 












5. Phytoestrogen interactions with variants of ERα/ERβ  
5.1 Introduction  
Variants and spliced forms of the ER have been reported in both normal breast 
tissue and in breast cancer; this has led to the hypothesis that outcomes in ER 
positive breast cancer might relate to the presence of wild type ER or variants 
in the ER. The wild type ERα (also known as ERα66) is the most prevalent form 
of ER found in breast cancer.  However, other ER isoforms have been reported 
(isoform 3, 4 and splicing variant ERαΔ5/6/7, ERαΔ3/4/5, ERαV) (Dixon and 
Oshiro 1995; Flouriot et al. 2000; Marino et al. 2006; Ohshiro et al. 2010; Rao 
et al. 2011). Isoform 4 (ERα36) has been reported to interfere with ERα66 
activity and negatively affect estrogen treatments of breast cancer (Wang et al. 
2005). Conversely, ERβ1 (Isoform 1) is associated with better survival in triple-
negative breast cancer as well as better response to Tamoxifen monotherapy, 
while nuclear ERβ2 (Isoform 2) levels have been shown to be associated with 
metastasis and vascular invasion and cytoplasmic ERβ2 linked to a poorer 
outcome(Thomas and Gustafsson 2011).  
 
The study of ERβ remains an important focus of current clinical research. ERβ1 
and ERΔ5 isoforms have been reported to be co-expressed in healthy 
mammary glands (Mandušić, Nikolić-Vukosavljević, Tanić, Kanjer, et al. 2007) 
and ERΔ5 may have inhibitory activity acting on both ERα and ERβ, and the 
high expression of this isoform has been linked to indicators of less aggressive 





The presence of different ER isoforms and the potential for dimerisation 
amongst the isoforms, alongside different expression levels in different 
cells/tissues provides an opportunity for a better understanding and 
development of different approaches for improving prognosis and treatment of 
cancer. The optimisation and validation of a docking approach to assess 
potential ligand interactions with the ER ligand binding domain (LBD) might help 
to better unravel the biological function of the natural ligands of the ER isoforms. 
It is expected that such an approach will also help to improve our understanding 
of the significance of phytoestrogen consumption in breast cancer patients 




The aim of the work presented in this chapter was to analyse, in silico, the 
interaction between phytoestrogen ligands and variants in the LBD of ERα and 











5.3 Results  
The ligand binding was assessed using the agonist and antagonist models 
generated in Chapter 4 and compared with the wild type LBD of ERα and ERβ 
and the LBD of different ERs subtypes. Models were built by homology 
modelling using agonist and antagonist conformations with template crystal 
structures extracted from the protein database as before the ligands (Estradiol 
(EST) and Tamoxifen (TAM)) were selected (ERα agonist PDB ID: 1GWR; 2.4 
Å, ERα antagonist PDB ID: 3ERT; 1.9 Å, ERβ agonist PDB ID: 2J7X; 2.1 Å, 
ERβ antagonist PDB ID: 2FSZ).  
 
Validation of the models was performed using well-described estrogen receptor 












5.3.1 The affinity of endogenous estrogens, drugs and dietary 
phytoestrogens to the LBD of ERα and ERβ isoforms using 
agonist and antagonist model templates. 
5.3.1.1 LBD ERα 
The AutoDock Vina free energy measurement tool was used to rank the affinity 
of interaction of estrogens, drugs and phytoestrogens to the homology models 
of the LBD of wild type and ERα isoforms in both the agonist Tables 5, Figure 
18 and antagonist Table 6 and Figure 19.  
Table 5. Agonist model of the affinity of estrogen and phytoestrogens to 
the LBD of wild type ERα and isoforms of ERα as shown. The computational 
docking program AutoDock Vina provided free energy values. The compounds 
have been listed alphabetically. Seco = secoisolariciresinol. ODMA=O-
desmethylangolensin 


















Estradiol -10.6 -8.4 -10.6 -8.8 
Estriol -7.4 -8.1 -7 -8.2 
Estrone -10.2 -8.5 -10.6 -8.9 
 Drugs Fulvestrant -7.1 -7.6 -6.7 -8.5 







Biochanin -7.9 -7.1 -7.9 -7.8 
Daidzein -8.5 -7.1 -7.6 -7.7 
Formononetin -7.6 -7.2 -7.6 -7.7 
Genistein -8.7 -6.9 -8.6 -7.9 
Glycitein -7.3 -7.1 -7.3 -7.3 




Matairesinol -6.9 -6.8 -7.2 -7.1 
Seco -7.2 -6.5 -6.5 -6.7 






Enterodiol -5.4 -5 -5.3 -5.1 
Enterolactone -9.1 -7 -9.1 -6.8 
Equol -7.2 -7.3 -8.8 -7.2 
















Figure 18. ERα LBD affinity to endogenous and exogenous ligands using 
the agonist template model in AutoDock Vina docking experiments. The 
lowest energy conformation per compound is shown. Wild type receptor: variant 
1 = ESR1_1; variant 2= ESR1_2, variant 3= ESR1_3, variant 4 = ESR1_4. 
 
As shown in Table 5 and Figure 18, above, the highest affinity interactions with 
the LBD of wild type ERα calculated by the AutoDock Vina system was for the 
estrogens (estradiol, estrone, estriol), also described in Chapter 4. Further 
analysis of binding to variant 3, which has an identical LBD to the wild type LBD 
of ERα, served as an internal control and the results obtained were almost the 
same as for wild type receptor. In addition, the isoflavones genistein, daidzein, 
and metabolites enterolactone, equol and ODMA all showed greater affinity to 
the wild type and variant 3 of the LBD of ERα than the lignans 
secoisolariciresinol, matairesinol and shonanin with binding energies for these 
phytoestrogens similar or greater than for Tamoxifen. The AutoDock Vina free-
energy binding values suggested that the LBD of ERα variants 2 and 4 bind 
more weakly to both Tamoxifen and phytoestrogen ligands than the wild type 





Table 6. Antagonist model of the affinity of estrogen and phytoestrogens 
to the LBD of wild type ERα and isoforms of ERα as shown. The 
computational docking program AutoDock Vina provided free energy values. 































Estradiol -8.8 -7.6 -7.8 -8.4 
Estriol -8.1 -7.3 -9.1 -8.4 
Estrone -10.2 -7.8 -8.1 -8.7 
Drugs 
  
Fulvestrant -10.1 -7.1 -9.8 -6.9 







Biochanin -6.8 -7 -6.9 -7.2 
Daidzein -9 -7.3 -7.7 -7.5 
Formononetin -7.7 -6.7 -7.7 -7.3 
Genistein -8.9 -7.2 -7.2 -8 
Glycitein -6.5 -7.2 -6.8 -6.9 




Matairesinol -6.9 -6.7 -6.8 -6.8 
Seco -5.9 -5.6 -6 -6.2 






Enterodiol -5.1 -5.7 -5.1 -5.2 
Enterolactone -6.6 -6.3 -8.2 -7.4 
Equol -8.9 -7.4 -8.3 -7.5 






Figure 19.ERα LBD affinity to endogenous and exogenous ligands using 
the antagonist template model in AutoDock Vina docking experiments. 
The lowest energy conformation per compound shown. Wild type receptor: 
variant 1 = ESR1_1; variant 2= ESR1_2, variant 3= ESR1_3, variant 4 = 
ESR1_4. 
 
When the LBD of ERα was investigated using AutoDock Vina using the 
antagonist model as the template as shown in Table 6 and Figure 19, the 
ranking of the binding partners in terms of affinity was much altered compared 
with the agonist model. In this scenario, estrone and Fulvestrant were found to 
be the most important binding partners (-10.2 and -10.1 Kcal/mol respectively), 
followed by daidzein, genistein and the metabolite equol (-9, -8.9 and -8.9 
Kcal/mol respectively).  
 
Tamoxifen was ranked 10th in terms of affinity of interaction with the LBD of ERα 
with lower affinity values than the phytochemicals above. The results from this 
analysis with the LBD of ERα suggest that daidzein, genistein and equol might 
all act as more potent antagonists of the LBD of wild type ERα than Tamoxifen, 
this suggests that the consumption and metabolism of isoflavones may result in 
a conformational change in the LBD of the receptor and warrants further 





drug and the exogenous dietary phytoestrogen ligands with lower affinity than 























5.3.1.2 LBD ERβ 
Table 7. Agonist model of the affinity of estrogen and phytoestrogens to 
the LBD of wild type ERβ and isoforms of ERβ as shown. The computational 
docking program AutoDock Vina provided free energy values. The compounds 
have been listed alphabetically. Seco = secoisolariciresinol. ODMA=O-
desmethylangolensin. Shaded yellow: physiologically occurring estrogens; pink: 






























































































Estradiol -10.7 -7.1 -6.2 -7.2 -6.5 -9.9 -7.3 -8 -9.1 
Estriol -10 -6.9 -5.7 -6.9 -6.6 -8 -7.5 -7.6 -7 
Estrone -10.4 -6.8 -6 -6.8 -6.9 -9.4 -7.6 -7.8 -9.6 
Fulvestrant -6.4 -6.5 -4.7 -6.1 -6.5 -8.5 -6.4 -7.2 -6.4 
Tamoxifen -6.3 -6.4 -5.9 -6.6 -6.7 -5.9 -6.2 -7.1 -5.8 
Biochanin -6.6 -6.4 -5.8 -6.4 -7.1 -8.3 -6.6 -7 -8 
Daidzein -8.4 -7 -5.9 -6.6 -6.6 -8.3 -6.7 -7 -8 
Formononetin -7.1 -7.1 -5.5 -7 -6.9 -8.2 -6.7 -6.9 -8 
Genistein -8.3 -7.2 -5.9 -6.5 -6.1 -8.3 -6.8 -7 -8 
Glycitein -6.5 -6.1 -6.1 -6.2 -6.4 -6.9 -6.5 -6.9 -7.9 
Narigenin -8.2 -6.7 -5.6 -6.4 -6.3 -7.9 -6.9 -7.7 -7.8 
Matairesinol -6.8 -6.4 -6.2 -6.5 -6.6 -6.2 -6.8 -7.2 -7.5 
Seco -5.9 -6.2 -4.9 -5.9 -5.1 -4.8 -6 -6.3 -5.8 
Shonanin -6.7 -6.5 -6.2 -6.8 -6.5 -6.8 -6.7 -7.1 -7.1 
Enterodiol -5.4 -5.4 -5.2 -5.1 -5.1 -5.6 -4.6 -4.3 -4.9 
Enterolactone -8.6 -6.2 -5.4 -6 -6 -7.3 -7.5 -7.6 -7.7 
Equol -8.5 -7.4 -5.7 -6.6 -6.3 -8.2 -6.7 -7 -8.5 





In the case of ERβ there have been nine variant (including the wild type) forms 
of the receptor described. The AutoDock Vina free energy measurement tool 
was used to rank the affinity of interaction of estrogens, drugs and 




















































































































Estradiol -7.6 -6.6 -6.5 -7.1 -6.5 -9.3 -6.8 -8.3 -7 
Estriol -8.9 -6.5 -6.4 -7.4 -6.9 -7.7 -6.6 -8.2 -7.5 
Estrone -9.9 -7.1 -6.4 -7.3 -6.9 -9 -6.9 -8.1 -9.2 
Fulvestrant -9.4 -7.7 -6.6 -5.6 -8 -8.4 -6.2 -7.9 -8.7 
Tamoxifen -7 -6.4 -5.7 -6.6 -6.3 -8.2 -7.3 -7.2 -6.4 
Biochanin -8.6 -8.5 -5.8 -8.4 -8.3 -8.3 -6.2 -7.4 -8.1 
Daidzein -8.9 -8.1 -5.7 -8.1 -8 -8 -6.1 -7.3 -7.9 
Formononetin -8.1 -8.2 -5.7 -8.1 -8.1 -8.1 -6.2 -7.3 -7.9 
Genistein -8.9 -8.4 -5.8 -8.3 -8 -8.2 -6.2 -7.4 -8.2 
Glycitein -7.7 -7.8 -5.4 -7.6 -7.1 -7.5 -6.2 -7.4 -7.2 
Narigenin -8.4 -8.1 -6.1 -8.5 -8.1 -8.1 -6.4 -7.7 -8.1 
Matairesinol -7.2 -7.3 -5.5 -7.1 -7.4 -7.4 -6.5 -7.8 -7.4 
Seco -6.9 -5.5 -5.2 -5.8 -6.6 -6.6 -6.2 -7.4 -6.4 
Shonanin -7.1 -6.8 -5.8 -7.4 -7.6 -7.3 -6.6 -7.6 -7.4 
Enterodiol -4.8 -5 -3.8 -6.4 -5.8 -4.8 -5.8 -4.6 -4.4 
Enterolactone -7.6 -7.5 -5.8 -7 -8.6 -7.4 -6.3 -8.1 -7.1 
Equol -8.6 -8 -5.7 -8 -8 -8 -6.4 -7.3 -8.3 
ODMA -8.2 -7.6 -5.8 -7.9 -7.7 -7.6 -6.1 -7.6 -7.8 
 
Table 8. Antagonist model of the affinity of estrogen and phytoestrogens 
to the LBD of wild type ERβ and isoforms of ERβ as shown. The 
computational docking program AutoDock Vina provided free energy 
values. The compounds have been listed alphabetically. Seco = 
secoisolariciresinol. ODMA=O-desmethylangolensin.Shaded yellow: 
physiologically occurring estrogens; pink: drugs; green: isoflavones; blue: 






As shown in Table 8, the highest affinity interactions with the LBD of wild type 
ERβ calculated by the AutoDock Vina system was for the estrogens (estradiol, 
estrone, estriol), also described in Chapter 4. In addition, a number of the 
isoflavones including genistein and daidzein, and the metabolites enterolactone, 
equol and ODMA all showed greater affinity to the wild type LBD of ERβ 
compared with tamoxifen, mirroring the observations that were made for ERα 
previously.  Again, the lignans secoisolariciresinol (-5.9 Kcal/mol), matairesinol 
(-6.8 Kcal/mol) and shonanin (-6.7 Kcal/mol) showed free-binding energies 
similar to Tamoxifen (-6.3 Kcal/mol). With the exception of variants 6 and 9, the 
AutoDock Vina free-energy binding values suggested that the LBD of the ERβ 
variants bind more weakly to both estrogens, Tamoxifen and phytoestrogen 
ligands than the wild type receptor.   
 
When the LBD of ERβ was investigated using AutoDock Vina using the 
antagonist model as the template as shown in Table 8 the ranking of the binding 
partners in terms of affinity was much altered compared with the agonist model. 
In this scenario, as for the LBD of ERα, estrone and Fulvestrant were found to 
be the most important binding partners (-9.9 and -9.4 Kcal/mol respectively), 
followed by daidzein, genistein and the metabolite equol (-8.9, -8.9 and -8.6 
Kcal/mol respectively). Tamoxifen was ranked 16th in terms of affinity of 







The results from this analysis with the LBD of ERβ mirror those obtained with 
ERα: suggesting that daidzein, genistein and equol might all act as more potent 
antagonists of the LBD of wild type ERβ than Tamoxifen, this suggests that the 
consumption and metabolism of isoflavones may result in a conformational 
change in the LBD of the receptor and warrants further investigation.   
  
5.3.2 Overview of affinity of estrogens to the LBD of ERα and ERβ 
The data obtained in the experimental approaches described above were 
compiled as shown in Figures 20 and 21 below. These give an overview of the 
binding properties of endogenous estrogens, drugs and phytoestrogens to the 
wild type forms of the LBD of ERα and ERβ in both the agonist and antagonist 
models used in this study.  As can be appreciated, endogenous estrogens, 
particularly estradiol are the most potent agonists of both ERα and ERβ. In terms 
of antagonists, somewhat surprisingly, Tamoxifen did not emerge as the most 
potent antagonist, rather estrone, some of the dietary phytoestrogens, including 
genistein, daidzein, equol and narigenin all appeared to show greater affinity in 
the antagonist form to ERα.  The results from both ERα and ERβ were very 








Figure 20. The affinity of endogenous and exogenous estrogens including 
dietary phytoestrogens to ERα. Blue: agonist model, orange: antagonist 
model. Output of docking experiments in terms of binding affinity (Kcal/mol); the 
lowest energy conformation per compound. Computational docking allowed the 
affinity values to be calculated by AutoDock Vina.  
 
Figure 21. The affinity of endogenous and exogenous estrogens including 
dietary phytoestrogens to ERβ. Blue: agonist model, orange: antagonist 
model. Output of docking experiments in terms of binding affinity (Kcal/mol); the 





5.4 Discussion  
The use of ER status as a companion diagnostic for determining the likely 
response of breast cancer patients to anti-estrogen treatments has been 
recognised for over three decades (Alldred DC, Modern Pathology (2010) 23, 
S52–S59).  At the time of its adoption in the late 1970s and 1980s the ER status 
(of ERα) was assessed using a ligand binding assay with radiolabelled estrogen 
and protein extracts from fresh tumour tissue extracts. This approach offered 
the advantage of being relatively physiologically relevant and also being directly 
quantifiable. However, the ligand binding assay was both expensive and 
technically challenging and since the early 1990s the ER status has been 
determined using immunohistochemistry in an approach approved by the 
College of American Pathologists and the American Society for Clinical 
Oncology (reviewed in Alldred DC 2010).  However, there remain difficulties in 
the standardisation of the immunohistochemistry methodology and on-going 
issues with intra- and inter-laboratory variation in results as a result of 
differences in tissue fixation, antigen retrieval and so on. The classification of 
ER status in breast cancer is, therefore, currently subject to inaccuracies and 
guidelines were recently published in recognition of this issue with aim of 
improving consistency across laboratories (Phillips et al. 2007). 
 
The discovery of ERβ in 1996 (Kuiper et al. 1996) and subsequent gene 
sequencing and identification of isoforms of both ERα and ERβ has resulted in 
further complexity around this class of receptors in breast cancer. In this study, 
the interaction between endogenous and exogenous estrogens and the LBD of 





were observed to behave similarly, with the free-energy binding values (affinity) 
ranked in the same order for both ERα and ERβ.  ERα variant 3 behaved the 
same as the wild type receptor.  
 
One of the main concerns around the consumption of dietary phytoestrogens by 
breast cancer patients is that phytoestrogens have the potential to interfere with 
anti-estrogen treatments such as Tamoxifen. Conflicting data has continued to 
emerge around this topic and this led to the independent panel of scientists at 
the World Cancer Research Fund’s Continuous Update Project conclusion that 
there may be a link between improved survival and the consumption of foods 
containing soy but that further research was needed into this topic (Aune et al. 
2012). 
 
This study was concerned with the potential estrogenic effect of dietary 
phytoestrogens as well as their possible interference with Tamoxifen therapy. 
The AutoDock Vina system was used to provide estimations for the free-energy 
of binding and this can be compared with data that has been obtained 
experimentally, estradiol along the other estrogen prove that they have stronger 
and more stable molecular interaction with the ERα β. At the same time 
genistein, daidzein and equol prove to be able to bind the ER in a lower affinity 
as have been previously reported in the literature. 
 
The results obtained in the experiments above suggest that the dietary 





greater affinity than estradiol.  Some of the phytoestrogens appeared to have 
greater affinity to the ERα and ERβ than Tamoxifen (in the antagonist model) 
but it is not clear as to whether the resulting structure occludes the binding of 
helix-12 (chapter 3) to the neighbouring monomer and therefore, this would 










6.1 Development of homology models of ERα and ERβ 
The aim of this research project was to assess the ability to apply structure-
based studies and computational tools to predict and describe the interactions 
of the ERα and ERβ with phytoestrogens and synthetic ligands. The first step 
(Chapter 3) was to develop protein (homology) models to use as targets to later 
assess the interaction with phytoestrogens (Chapters 4 and 5). Homology 
modelling has helped researchers to narrow the space between structural 
modelling from experimental work and protein sequences leading to the 
production of models of proteins that have been difficult to crystallise or unravel 
by NMR spectroscopy. Since more than 300 3D-structures of wild type ER are 
available in the Protein database (URL www.rcsb.org; Berman et al., 2000) the 
criteria used to select possible templates were based on the resolution of the 
crystal or NMR structure, ligand binding interactions and the 3D conformations. 
The performance of the models to re-dock the respective ligands derived from 
their own templates and to emulate the poses of the original ligands enabled an 
assessment of the utility of the model.  These models offer the opportunity for 
further studies for example mutagenesis studies using in situ or amino acid 
substitution and docking with a wide range of possible ligands.     
 
There are several tools to assess and validate the models including quality 
estimation approaches which assess the specific features of the model such as 
the sterochemical quality of the interactions (Morris et al. 1992), structure 





potentially unreliable parts of the protein model structures (Wiederstein and 
Sippl 2007) or web-servers that can complement and provide extra information 
about the models (Willard et al. 2003). The best assessment approaches rely 
on the consensus provided by a whole range of in silico validation tools. QMEAN 
is considered an important tool for the quality assessments of homology models 
and increasing the performance of the score through the combination of different 
terms and the QMEAN Z-score provides further data about the absolute quality 
of the predicted homology models. 
 
Homology modelling was first applied to model the wild type isoform of each 
receptor (α and β). AutoDock Vina was used for the molecular docking and also 
provided a binding energy score. Afterwards, the isoforms for the ligand binding 
domain of both ERs were built based on the same template with two models 
built per isoform. The first approach was to produce a model on an agonist 
complex and the second in antagonist conformation. This is particularly 
important when considering potential ER interaction partners as several 
hormonal treatments for breast cancer (including Tamoxifen) act as antagonists, 
whilst receptor stimulation occurs via the agonist properties of estradiol and 






6.2 Docking studies with estrogens, drugs and phytoestrogens 
Molecular docking is a valuable approach to understanding receptor-ligand 
interactions and work in many research laboratories has illustrated the value of 
this approach  (Yuriev and Ramsland 2013).  The creation of new, and 
improvements to, existing algorithms has resulted in improvements in 
performance of molecular docking systems (Xu and Lill 2013). Furthermore, this 
field has greatly benefited from the research advances in fields such as first 
principle thermodynamics and computer developments, that have been applied 
to help refine the programmes as well as to aid understanding of the results 
(Dahlqvist, Meshkian, and Rosen 2017). At the same time the use and 
understanding of bioinformatics in research laboratories has evolved such that 
it is now a mandatory field of knowledge for those active in many areas of 
molecular and biomedical sciences. These diverse developments have resulted 
in the creation of somewhat more user-friendly tools for biology in order to allow 
the researcher to focus on interpretation of data collected rather than forcing 
them to develop and understand complex equations and algorithms (Trott and 
Olson 2010b).  
 
Docking analysis of estradiol and phytoestrogens into the LBD of ERα and ERβ 
showed the intrinsic quality of these natural polyphenolic compounds to emulate 
the estradiol-like docking poses and possibly alter the conformational internal 
structure of the ligand binding pocket (and potentially the conformation of whole 
protein structure). At the same time, as a function of its complex algorithm, 
AutoDock Vina had the capacity and accuracy to predict the binding 





through the experimental data and described in the literature. Also, there was a 
correlation between the binding affinities reported in the literature with the 
values of the free-energy binding that were obtained using the docking system. 
As expected estradiol showed the greatest affinity (lowest free-energy binding) 
of the structures assessed, consistent with reports that estradiol is the most 
potent ligand of all the estrogens to ERα (Hall et al. 2001). 
  
6.3 Significance of the results obtained 
We hypothesised that natural ligands with estrogen-like structures might drive 
ER-related biological functions and therefore might have the ability to affect 
breast cancer outcomes. These potential effects would depend upon the 
molecular profile of the breast cancer and may be relevant to patients with both 
ER+ and ER- breast cancer, affecting the efficacy of clinical treatments that 
target the ER.  
 
Natural compounds such as dietary phytoestrogens vary according to the plant 
strains from which they derive, the agricultural conditions (including harvest 
time), food preparation and food composition alongside their bioavailability. 
Furthermore, based on scientific evidence obtained from epidemiological 
reports, case studies, in vitro and in silico experiments it is clear that differences 
in exposure to phytoestrogens will occur in an intra- and inter-individual manner. 
This may be due, for example, to differences in the proportions of different 
phytoestrogens consumed, the presence of aglycol-derivatives, compound 
concentration and metabolism (Dixon 2004; Hwang and Choi 2015; Swann et 





system and recognise that the mechanisms by which this highly heterogeneous 
group of natural compounds interact with the ER might have potential positive 
but as yet unmeasured impact on breast cancer biology. Identifying and 
understanding the molecular interactions of such compounds with the ER is the 
first step in understanding their biological impact in breast cancer. The impact 
of three estradiol analogs on intracellular signalling pathways has been reported 
and described the ability of estrogen-like molecules to alter gene expression 
levels depending on the ligand binding interactions  (Yarger et al. 2013).  Whilst 
it will be necessary to validate the work of the study performed here using in 
vitro experiments to determine if the binding affinities and free-energy binding 
values truly correlate with estrogenicity of the compounds described, the system 
described has much potential as a screening tool for the assessment of 
chemicals such as xenoestrogens (and other exogenous compounds) which 

















An important consideration when evaluating in silico modelling is whether the 
docking results obtained mimic the behaviour of the ER in vitro. Since the main 
goal of this research was to investigate the interactions between the ER and 
phytoestrogens, ideally, full length ER needs to be produced. Mammalian cells 
and a baculovirus system have been shown to be of utility in this respect but 
these are costly, time-consuming systems which are difficult to reproduce. An 
alternative approach is to express only the LBD of the ER. This has been 
feasible with the LBD of wild type ERα and ERβ isoforms successfully cloned, 
expressed and purified in a good yield using an expression system which adds 
a small ubiquitin-related modifier (pET-SUMO) that helps to stabilise the 
recombinant protein. So far it has not been possible to purify each variant of 
each ER isoform but they have been expressed and optimisation steps for the 
purification are on-going (data not shown here).  The purified ER proteins will 
be used in a fluorescence polarisation ligand binding assay and the plasmid will 











6.5 Future work 
The use of in silico work with AutoDock Vina and other open source 
bioinformatics tools have provided an insight data into the possible interaction 
between a wide range of phytoestrogen compounds and the LBD of ER and its 
variants. Further work in terms of analysis of these interactions is needed with 
an experimental approach using laboratory based screening; this will constitute 
an important approach for comparing the in silico and the in vitro data allowing 
for the prediction and design of further in vitro and in vivo experiments. Another 
important approach will be to assess the effect of these compounds in terms of 
promoting breast cancer cell proliferation. This might be evaluated by addition 
of different concentrations of estrogens (E1, E2, E3) (Kumar et al., 2011), 
phytoestrogens: genistein, daidzein, coumestrol, equol (Rice et al., 2008; 
Setchell et al., 2010) and synthetic agonists and antagonists (TAM, ICI 182,780) 
(Pearce and Jordan 2004). Ligand-free controls (for example only ethanol) will 
need to be produced with each ligand assessed on its own and in combination 
with different concentrations of other ligands presented in the study. As the LBD 
of the ER is not directly related to its transcriptional activity the selectivity of 
phytoestrogens for ER subtypes and isoforms may be influenced by ligand 
concentration. Furthermore, in order to measure transcriptional activity cell-
based assays need to be used based on reporter systems such as the ERE-
luciferase reporter methodology. 
 
The DietCompLyf study is a multi-centre observational study that is coordinated 
by the Cancer Research Unit at the University of Westminster (Principal 
Investigator: Dr Dwek). The DietCompLyf study is focussed on determining the 





(Velentzis et al., 2011). A key element of the DietCompLyf study is the availability 
of questionnaires giving a snap shot of food intakes alongside biological 
samples enabling analysis of phytoestrogen intake, biomarker levels and 
correlation with clinical treatments and patient recurrence rates. The database 
of the DietCompLyf study counts comprises around 3,144 women. A separate 
nested case control cohort of around 200 patient matched with all the clinical 
criteria is available. All the subjects have provided a food frequency 
questionnaire, and a 7-day food diary allowing the phytoestrogen levels to be 
estimated in addition their urinary phytoestrogen levels which have been 
quantified by liquid chromatography/tandem mass spectrometry(LC–MS/MS) 
(Grace et al. 2007). The findings of the in silico and in vitro experiments from 
the work described in this thesis will be compared with data and samples 
collected as part of the DietCompLyf study. 
 
6.6 Conclusion 
The work described in this thesis has shown the potential of homology modelling 
and ligand docking for unravelling interactions between physiological estrogens, 
hormone therapies and dietary phytoestrogens and the ER.  The models have 
been interrogated in terms of the residues recognised as well as the free-energy 
binding values and have been found to correlate with experimentally derived 
values.  The system developed offers considerable potential for the screening 
of chemicals which might be important in driving breast cancer progression 
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Amino acid sequence 
P03372 
ESR1_HUMAN 
Estrogen receptor  


















Table 1. Human estrogen receptor wild type sequence full length and ligand 
binding domain, as retrived from Unitprot database (06-06-13). 
 
 





















Table 2. cDNA Estrogen receptor wild-type full length. Optimized sequence for 




Product name and size Primer forward 5’ -3’  Primer reverse 5’ – 3’ 
pET – SUMO Plasmid AGATTCTTGTACGACGGTATTAG TAGTTATTGCTCAGCGGTGG 
Ace-pETSumo  ATGAAAAAAAACAGCCTGGCACTGAGC TAGTTATTGCTCAGCGGTGG 
ESR1 WT full length ATGCCATGACCCTGCATACCAAA TTAAACTGTTGCCGGAAAACCTTCT 
ESR1 LBD ATGAAAAAAAACAGCCTGGCACTGAGC TTAGGTCGGTGCATGCAGACGATG 
 
Table 3. Primer designed for pET-SUMO plasmid, ESR1 full length and ESR1 
LBD. 









Cluster aligment ER alpha ligand binding domain wiltype and isoforms  
 
ESR1              KKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWA 
ESR1_2          ----------------------------------------------------------------------------------------------------------------------- 
ESR1_3          KKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWA 
ESR1_4          KKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWA 
 
ESR1              RVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGM 
ESR1_2          ----------VDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGM 
ESR1_3         RVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGM 
ESR1_4         RVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGM 
 
ESR1              VEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDK 
ESR1_2          VEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDK 
ESR1_3          VEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDK 
ESR1_4          VEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGFTISHVE------------AKKRILNLHPK 
 
ESR1              ITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLL 
ESR1_2          ITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLL 
ESR1_3          ITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLL 
ESR1_4          IFGNKWF--P-----------------------RV----------------------------------------------------------------------- 
 
ESR1           EMLDAHRLHAPT 
ESR1_2          EMLDAHRLHAPT 
ESR1_3          EMLDAHRLHAPT 
ESR1_4          ------------------------ 
Table 4. Cluster aligment ER alpha ligand binding domain wiltype and 
isoforms. Isoform 2 is missing 
KKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADREL
VHMINWAKRVPG) at the LBD, Isoform 3 possess the same LBD than the 
wild type and isoform 44 possess aa FTISHVEAKKRILNLHPKIFGNKWFPRV 











Cluster aligment ER Beta ligand binding domain wild-type and isoforms 
 
ESR2    VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_2  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_3  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_4  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_5  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_6  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_7  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_8  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
ESR2_9  VKCGSRRERCGYRLVRRQRSADEQLHCAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLE 
 
ESR2     AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESC 
ESR2_2  AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESC 
ESR2_3 AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGMRGNA--------------------- 
ESR2_4  AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESC 
ESR2_5  AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESC 
ESR2_6  AEPPHVLISRPSAPFTEASMMMSLTKLADKELVHMISWAKKIPGFVELSLFDQVRLLESC  
























ESR2_7  --------------------------------MYPLVTATQDADSSRKLAHLLNAVTDALVWVIAKSGISSQQQS 










ESR2_8  ----------------------------------------------------------------------------------------------------------------------- 
ESR2_9 MRLANLLMLLSHVRHARSCVYK---------------------------------------------------------------------------- 
ESR2 SPAEDSKSKEGSQNPQSQ 
ESR2_2  -EQ----------------------------- 
ESR2_3 ---------------------------------- 
ESR2_5  ---------------------------------- 
ESR2_4 SVSRSRSFEACQQPRE- 
ESR2_6  ---------------------------------- 
ESR2_7 SPAEDSKSKEGSQNPQSQ  
ESR2_8 ---------------------------------- 
ESR2_9  ---------------------------------- 
 
Table 5. Cluster aligment ER Beta ligand binding domain wild-type and 
isoforms. Isoform 2 displays  SNKGMEHLLN...KEGSQNPQSQ → 
RAEKASQTLTSFGMKMETLLPEATMEQ,  Isoform 3 319-323: FVELS → 
MRGNA and is missing  aa 324-530, Isoform 4 
SNKGMEHLLN...KEGSQNPQSQ → SSLSLSWRLF...SFEACQQPRE, Isoform 
5 differs from wild type sequence in aa 469-530: 
SNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGCKSSITGSEC 
SPAEDSKSKEGSQNPQSQ, Isoform 6 The sequence of this isoform differs 
from the wild type sequence    469-530: 
SNKGMEHLLNMKCKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAED 
SKSKEGSQNPQSQ, Isoform 7 is missing aa 319-409, Isoform 8 is missing aa 
376-530 and displays 365-375: DEGKCVEGILE → YVPSGHSDPGC, Isoform 










LBD sequences of Estrogen Receptors isoforms 















































































Table 6. Protein sequences of LBD estrogen receptor isoforms. Isoform 1 































2.1 ER-α Wild type 
Estradiol vs ER-α WILD TYPE 
 
Figure 1. Estradiol binding estrogen receptor Α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Green ligand on the left and model was taken from PDB database (1GWR) and the red 







Estradiol vs ER-α WILD TYPE 
 
Figure 2. Estradiol binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand based on the Autodock Vina pose. Green ligand on the left and model was taken from 








Estriol vs ER-α WILD TYPE 
 
Figure 3. Estriol binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand based on the Autodock Vina pose. Green ligand on the left and model was taken from 







Estrone vs ER-α WILD TYPE 
 
Figure 4. Estrone binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand based on the Autodock Vina pose. Green ligand on the left and model was taken from 








Daidzein vs ER-α WILD TYPE 
 
Figure 5. Daidzein binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 







Enterolactone vs ER-α WILD TYPE 
 
Figure 6. Enterolactone binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 
2D representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced 






ODMA vs ER-α WILD TYPE 
 
 
Figure 7. ODMA binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






Genistein vs ER-α WILD TYPE 
 
Figure 8. Genistein binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 








ERα Antagonist template model vs Tamoxifen 
 
Figure 9. Tamoxifen binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the blue ligand is pose produced by 







ERα antagonist template model vs genistein 
 
Figure 10. Genistein binding estrogen receptor α, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 







2.2 ER-β Wild type 
Estradiol PDB file vs ERβ wild type 
 
Figure 11. Estradiol binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 







Estradiol vs ERβ wild type 
 
Figure 12. Estradiol binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






Genistein vs ERβ wild type 
 
 
Figure 13. Genistein binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






Daidzein vs ERβ wild type 
 
Figure 14. Daidzein binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






Equol vs ERβ wild type 
 
Figure 15. Equol binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






ODMA vs ERβ wild type 
 
Figure 16. ODMA binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 






Enterolactone vs ERβ wild type 
 
Figure 17. Enterolactone binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 
2D representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced 







Enterolactone vs ERβ isoform 5 
 
Figure 18. Enterolactone binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 
2D representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced 







Enterolactone vs ERβ isoform 8 
 
 
Figure 19. Enterolactone binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 
2D representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced 






ERβ Antagonist template model vs Tamoxifen 
 
Figure 20. Tamoxifen binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 







ERβ Antagonism model vs Genistein 
 
Figure 21. Genistein binding estrogen receptor β, on the right cartoon representation of the amino acid interactions. On the left 2D 
representation of binding pocket and ligand. Model template based on agonist conformation and the red ligand is pose produced by 




























































3.1.1.1 Estrogen receptor full length sequence and expression 
 
Wild type estrogen receptor protein sequence was retrieved from Uniprot 
database (http://www.uniprot.org). Due to the chosen expression system, ERα 
cDNA sequence was optimized for E. coli expression in order to avoid rare 
codons. WT ERα optimized sequence was verified and synthesized by GeneArt 
synthesis service at life technologies. 
 
3.1.1.2 Insertion of WT ERα in pET-SUMO vector   
pET-SUMO vector was used as expression system, allowing the direct insertion 
of a PCR product; primers for the insert were according to the instructions in the 
manual. Amplification of the WT ERα DNA was produced using PCR 
Supermaster mix (Invitrogen); 45 µl PCR SuperMix, 4 µl primer mix and 1µl of 
template DNA solution (pMX plasmid kanamycin resistant+ WT ERα supplied 
by Invitrogen). Reaction was mixed and loaded in the BioRad DNA Engine 
Thermocycler; PCR conditions were optimized for 35 cycles (94°C x 30”, 60°C 
x 30” and 72°C x 1’). PCR products were resolved in 2% (w/v) agarose gel in 






3.1.1.3  Ligation 
After verification of a single right size product (approximately 1865 bp), PCR 
product purification was performed using QIAquick PCR purification kit (Qiagen, 
UK) according to the manufacturer’s instructions. For optimal ligation efficiency 
a fresh PCR product was used (less than 16 hr). The ligation reaction was 
prepared with 1 µl PCR product, 1 µl 10X ligation buffer, 2 µl pET-SUMO 
plasmid, 5 µl sterile water, 1µl T4 DNA ligase and incubated at 15 °C overnight 
and stored at -20 °C. 
 
3.1.1.4  Transformation, colony selection and insert analysis 
After ligation of the insert (WT ERα) into pET-SUMO, the vector was used for 
transformation into competent cells (One shot Mach1-T1 supplied by 
Invitrogen). 2 µl of the ligation reaction was pipetted into a vial of One Shot 
competent cells, without mixing or pipetting up or down. The respective vial was 
incubated on ice for 30’. After incubation cells were heat shocked for 30” at 42°C 
without shaking.  The vial of competent cells was incubated in ice for other 15’ 
and at room temperature pre-warm 37°C SOC media was added, mixture was 
shaked at 37°C at 250 rpm for 1 hr. Afterwards 100 µl of the mixture were spread 
on selective agar plates (LB agar, 50 µg/ml kanamycin) and incubated overnight 
at 37°C. After overnight incubation, one colony was used to inoculate 10 ml of 
LB (Kanamycin 50 µg/ml) for plasmid extraction and insert analysis. QIAgen 
Spin Miniprep kit was used for plasmid isolation, according to the manufacturer’s 





sequencing (GATC Biotech Sanger sequencing), Insert orientation was 
evaluated using primers previously designed in the study for the insert (ESR1 
forward and ESR1 reverse) and primer designed for pET-SUMO vector (pET-
SUMO forward and T7 reverse) orientation test was performed in a PCR 
reaction using a mix primer solution (pET-SUMO forward and ESR1). 
 
3.1.1.5 BL-21 transformation and pilot expression 
pET-SUMO+ESR1 plasmid  was used for pilot expression in E. coli BL21(DE3) 
supplied by Novagen, competent cells were thawed in ice and 1 µl of plasmid 
(pET-SUMO+ESR) was added and incubated for 30’ in ice. Afterwards 
competent cells were heat shocked at 42 °C for 30’’, 250 µl of SOC medium was 
added to the vial, the mixture vial was incubated at 37 °C for 1 hr and shaken at 
250 rpm. The entire transformation reaction was added to 10 ml of LB with 
kanamycin (50 µg/ml) and incubated overnight at 37 °C with shaking at 250 rpm 
to proceed to the pilot expression. 10 ml of LB kanamycin 50 µg/ml was 
inoculated with 500 µl of the overnight culture; broth was incubated at 37 °C in 
at shaking incubator for 2 hr, and after reaching the mid-log phase of the culture 
(0.6 OD600 nm) split into two 5 ml cultures. One of the vials was induced with 1 
IPTG mM, 500 µl was removed from each vial (Induced and uninduced) and 
centrifuged for 30’ at maximum speed in a micro-centrifuge, the supernatant 
was discarded and the cell pellet was stored a -20 °C then labelled as a zero 
point. Both cultures were incubated at 37 °C with shaking and an aliquot of 500 
µl of time points was taken every hour for 6 hours, each time point was 






3.1.1.6 Analysing samples and SDS-PAGE  
Samples were analysed by SDS-PAGE on10–4 % acrylamide gels, samples 
were thawed and mixed with 80 µl of Laemmli sample buffer. Mixtures were 
boiled for 5’ and briefly spun in a table micro centrifuge at maximum speed. An 
electrophoresis chamber (mini-PROTEAN Tetra Cell Bio Rad) was previously 
prepared with running buffer (Appendix 4, page 1) and two gels, 5 µl of the 
induced and uninduced samples were loaded in the pre-cast gels along with a 
protein marker (SeeBlue Pre-Stained Standard) at both gels as a duplicate. Gels 
were run for 1 hr at 110 V, then, gels were washed twice for 5’ with ddH2O. Gel 
was stained Coomassie Brilliant blue stain overnight at room temperature. 
Staining was removed by destain solution for about 4 hr. 
 
3.1.2.1 Optimization of the expression levels  
In order to increase the yield of the soluble protein and overcome proteolytic 
cleavage, instability and precipitation, the protein expression protocol was 
modified in different steps ranging from the composition of the medium to the 
cell lysis conditions. IPTG induction was tested under different concentrations 
(0.2, 0.5,1 and 1.5 mM IPTG), LB broth was supplemented with estradiol and 
sucrose, incubation temperatures were tested at 15, 18, 25 and 37 °C and the 
time for induction was varied from 18, 12, 4 and 3 hr respectively and, finally, 
the use of a cocktail of protease inhibitors (Sigma Aldrich; 1:100) in the cell lysis 





tested separately and finally combined. Samples were assessed by SDS-PAGE 
gels and Western blotting as before. 
3.1.2.2 Western blot 
To detect the expression levels of the ER by Western blotting, an anti-HisG 
antibody (Invitrogen) was used.  Blotting was performed as shown in (Appendix 
3, figure 4) with 100 Volts for 2 hours. Afterwards, membrane was blocked using 
5 % w/v BSA in TBS overnight at 4ºC, blocking buffer was removed and the 
membrane was submerged with 5 ml of the diluted 1:2000 AP-conjugated 
antibody (Anti-HisG Invitrogen) into TBS for 2 hours at room temperature. NBT 
and BCIP substrates were used for detection of the alkaline phosphate probe; 
33 μl NBT and 16.5 μl BCIP were added to 5ml of alkaline phosphatase buffer 
(Appendix 4). After washing the membrane in TBST twice for 5 minutes with 
gentle agitation, the membrane was rinsed and placed in a dish with 5 ml of the 
BCIP/NBT substrate solution for about 5 minutes until the colour developed.  
The reaction was stopped by washing the membrane in ddH2O, membrane were 
air-dried and photographed.   
 
3.1.3  Estrogen receptor LBD expression  
According to the Uniprot database the estrogen receptor ligand binding domain 
(LBD) falls between aa 302 to the aa 549  of the estrogen receptor sequence 
(P03372 - ESR1_HUMAN).  The cloning segment was based on literature 
reports according to its solubility and expression yield [332 aa to 552 aa] (Eiler 
et al. 2001). The optimized WT ESRα described above was use to extract the 





selection and expression were performed according to the instructions in the 
pET-SUMO manufacturer’s manual and as described above (Sections 
3.1.1.2/3/4/5/6). 500 µl of overnight culture of the transformation vial BL21 (pET-
SUMO + ESR1/LBD) was inoculated in 10 ml of LB 50 µg/ml kanamycin at 37 
ºC for approximately  2 hour or until it reached the mid-log phase (0.4-0.6OD600 
nm), 500 µl of broth was added to 50 % v/v glycerol in 2 ml cryovial tube and 
mixed gently. Bacterial glycerol stocks were frozen at -80 ºC. 
 
3.1.3.1 Scaling-up expression and purification   
Expression was scaled up to 500 ml bacterial culture for protein purification 
using HisPur Ni-NTA resin. The glycerol stock of the transformed BL21 (pET-
SUMO + ESR1/LBD) cells were used. The stock was inoculated into LB 
containing kanamycin at 50 µg/ml and grown overnight at 37 ºC. 5 ml of the 
overnight broth culture were used to inoculate two 2 l flasks each containing 250 
ml of LB with kanamycin 50 µg/ml.  The cultures were incubated for 2.5 hours 
at 37 ºC with shaking at 259 RPM until mid-log was reached (0.6OD600), flasks 
were cooled down in ice-cold water for 30 min. IPTG was added to final 
concentration of 1mM in both cultures and incubated at 25 ºC for 4hr. Cells were 
collected by centrifugation (3000 x g for 10’ at 4ºC), supernatant was discarded 
and pellet suspended in 5 volumes of the bacterial PELB buffer, lysozyme were 
added to a final concentration of 100 µg/ml. The suspension was incubated for 
1 hr on ice and sonicated in a beaker of ice at 40%, 5x10” bursts with intermittent 
cooling. Debris were removed by centrifugation at 11,000 x g, 30’ 4ºC. The 
supernatant was removed and prepared by overnight dialysis at 4ºC in 1l of 





the column was equilibrated with 9 ml binding buffer; the prepared protein 
extract was added. 12 ml of wash buffer were added to the column and an eluted 
with 10 ml elution buffer, Amicon ultra-15 centrifugal filters (MWCO 10 kDa) 
were used for protein concentration for a final volume of 1 ml. The final protein 
concentration were monitored by measuring the absorbance at 280 nm. Finally, 
the protein was desalted using a PD-10 column (GE Healthcare) previously 



















3.1.4  Competitive ligand binding assay 
 
3.1.4.1 Fluorescent polarization Assay: Polar-Screen Estrogen 
receptor (ER) alpha competitor assay 
The PolarScreen™ Estrogen Receptor Alpha (ER Alpha) Competitor Assay, 
Green (Life technologies) was used to determine IC50 values of different 
endogenous and exogenous Compounds in the full-length ER alpha. The test 
compounds were 3 endogenous and natural ligands (estradiol, estriol, estrone), 
a commercial drug Tamoxifen and 5 different PEs (genistein, daidzein, 
coumestrol, secoisolaricinol and enterodiol). Firstly, it was use to determinate 
IC50 values of the tested compounds and secondly to test the LBD-ER alpha 
cloned in the previous experiment using the Fluormone™ ES2 Green as 
selective fluorescent ligand. The binding affinity of the tested compounds were 
measure in a range of 12 concentrations (serial dilutions), with a final 
concentration of 41nM of full-length ER-Alpha and 4.5 nm Fluormone ES2.  
 Assay Controls    
Component  Test 
compound  













- - - 10 µL 
2XTest Compound 
(titrations) 
10 µL - - - 
2XERAlpha/Fluormone 
ES2 Green Complex 
10 µL - 10 µL 10 µL 
2X Fluormone™ ES2 
Green 
- 10 µL - - 
ES2 Screening Buffer - 10 µL 10 µL - 
Table 1.Reagents volumes, reagents amounts required to perform the 






Three different plates were use in the experiment the first two plates were for 
serial and intermediate dilutions (384-deep well, uncoated, polypropylene plates 
that can accommodate 240 µL per well; plate must be tolerant of 100% DMSO, 
Corning, Cat. no. 3363) and an assay plates (low-volume 384-well plates with 
non-binding surface Corning, Cat. no. 3820). Final volume of the assay per well 
was 20 µl and DMSO were used as a solvent. 10 µl of the NR buffer of the NR 
buffer was aliquoted to each well in column 1 and 2 of the final assay plate. 
Ligand stock were prepared at 1mM (100x), and the respective serial dilution 
were done in the dilution plate adding 20 µl per well from B to P rows, 30 µl of 
the 1mM ligand stock in A row were added per compound. 10 µl were 
transferred from well A1 to B1 then from B1 to C1 and this process was repeated 
until reached the last row (P). Afterwards, it was added 98 µl of NR buffer in the 
required number of columns in the intermediate dilution plates to dilute each 
compound from 100x to 2x after adding 2 µl from each well in the dilution plate 
to the respective ID well in the intermediate dilution plate. Finally, 10 µl of the 
2x intermediate dilution were added of each compound by duplicate in the final 
assay plate. All the reagents were added according to the table 1 in the 
respective columns and wells, the assay plate was mixed and cover from light. 
After 2 hours incubation at 25 0C the Fluorescent polarization was measure in a 
Perkin-Elmer plate reader (EnVision 2104 Multilabel reader, software; Wallace 
manage version 1.12) using filter 535 nm for excitation and 590 nm for emission. 
Binding parameters were calculated by non-linear regression using GraphPad 







3.1.4.2 Ligand binding domain screening  
Assessment of the LBD domain ER alpha were performed using the 
PolarScreen™ Estrogen Receptor Alpha (ER Alpha) Competitor Assay, Green 
kit. By replacing the full-length provided ER-alpha by the in house produced 
LBD-ER alpha and tested for estradiol binding affinity in order to find the optimal 
concentration to provide at least a 150 mP Delta mP (Difference between the 



























3.2.1 Estrogen receptor cloning and expression in E. coli 
The full length estrogen receptor sequence (Appendix 1 table 1), reverse 
transcribed and  optimised to take into account the rare codon usage were 
prepared and  delivered by Invitrogen in a kanamycin resistant plasmid to 
facilitate selection in E. coli.  Primers for amplification of the insert were 
designed according to pET-SUMO manual instructions. A pcr product was 
generated, purificated and checked for size (1785 bp) by electrophoresis. The 
1785 bp purified product was used as an insert in the pET-SUMO linear plasmid 
and after ligation transformation was performed in presence of 50 µmg/ml of 
kanamycin agar plate. 10 colonies were chosen after overnight incubation and 
after plasmid extraction and purification a PCR were run using pET-SUMO 
primers, ESR1 primers and a mix between both in order to check the right 
orientation of the insert. The plasmid of the correct orientation was sent for 
sequencing and no mutations were observed. This was then used for 
transformation and expression experiments in BL21 (DE3) cells, after pilot 
expression and analysis using SDS-PAGE poor expression levels were 
observed and proteolysis apparent. In order to improve the level of expression, 
the solubility and to overcome issues with proteolysis, different conditions were 
tested as described in the materials and methods, these ranged from varying 
the incubation temperature, IPTG concentration, supplements and lysis buffers 








       A.SDS-PAGE       B. Western blot 
Figure 1. Expression of full 
length ESR1 WT with SUMO tag 
in BL21(DE3).Protein was 
expressed in native state in 
BL21(DE3), Experimental 
conditions: Cells were induced with 
1mM IPTG and incubated at 25 ºC 
for 4 hr with shaking at 250 RPM. 
Lane M1 and M2: pre-stained 
protein markers (M1 SeeBlue Plus2 
Invitrogen, M2 Precision plus 
protein Bio-Rad). L1: un-induced fraction BL21 cells lysis, L2: Induced whole 
cell lysed fraction. On the right A; Samples were separated using SDS-PAGE 
(10% gel) with Coomassie Brilliant blue staining and analysed (on the left) B; 
Western blot with 6HIS antibody, binding of antibody was displayed by   
colorimetric detention (BCIP/NBT).         
 
3.2.2 Estrogen receptor LBD expression 
After unsuccessful attempts and evaluation of various approaches to express 
the full length ER WT protein, it was necessary to focus in the LBD which has 
already been expressed under different conditions and with bacterial expression 
systems, and in order to improve the recombinant protein solubility the pET-
SUMO plasmid system was employed as well. After plasmid construction (pET-
SUMO LBD) plasmid size, orientation and sequence were assessed, these were 
found to display the correct sequence. Conditions used for the expression as 
per the flow chart after SDS-PAGE analysis, the best conditions observed were 






Figure 2. Expression Estrogen receptor ligand binding domain with SUMO 
tag in BL21 (DE3) and purification of His-tagged protein. Protein was 
expressed in native state in BL21(DE3), Experimental conditions: Cells were 
induced with 1mM IPTG and incubated at 25 ºC for 4 hr with shaking at 250 
RPM. SDS-PAGE  analysis of Coomassie Brilliant blue stained gel  for 
visualisation. Lane M1: pre-stainedprotein markers (SeeBlue Plus2 Invitrogen). 
L1: un-induced fraction BL21 cells lysis, L2: Induced whole cell lysed fraction, 
L3: in-soluble fraction, L4: soluble fraction. Soluble fraction was used for affinity 
purification of the His-tagged protein; L5: flow-through fraction, L6: eluted 
fraction. All the eluted fractions were pooled and concentrated using an amicon 
Ultra-15 centrifugal filter, L7: concentrated recombinant purified protein (ESR1 
LBD +SUMO). 
 
During the purification steps the protein displayed less precipitation and when 
expression was performed at 4ºC from 500 ml of LB broth 8 mg/ml of soluble 
protein was purified (Figure 6), The shelf life before precipitation was around 2 
weeks at 4ºC. This protein has now been stored at -20 ºC in storage buffer (25 











3.2.3  Competitive ligand binding assay 
 
3.2.3.1 Fluorescent polarization Assay: Polar-Screen Estrogen receptor 
(ER) alpha competitor assay 
Competition binding experiments are used to determine affinities of non-labelled 
ligands, in which it can be compared the relative binding affinity (IC50) and Ki 
when the labelled ligands Kd is known. Calculating binding affinities without 
labelling the studied ligands is one of the benefit of fluorescent polarization (FP). 
FP and IC50 were measured using the Polar-Screen Estrogen receptor (ER) 
alpha competitor assay, green kit (Invitrogen, UK). Serial dilutions of the 
interested compounds were done ranging from 10 µM to 56 pM; FP was 
measured using an Perkin Elmer plate reader (EnVision serial number 1040476) 
using for excitation filter (FITC FP 480), Emission filter (FITC FP P-pol 535) and 
FITC FP S-pol 535 as a 2nd emission filter. Coordinates of the corners of the 
384 plate were set at 12.13 mm x 8.99, 115.63 mm x 8.99 mm, 12.13 mm, 76.49 
mm, and 115.63 mm x 76.49 mm. measure height 6.5 mm, excitation light 75%, 
G factor 1, Detector gain 500 and 700 and a 30 number of flashes. FP value 
blank corrected were calculated (1000*[(S-Bs)-G*(P-Bp)]/[(S-Bp)+G*(P-Bp)] 
where S; FP fluorescein channel 2 [535s], P; FP fluorescein channel 1 [535p], 
G; G-factor, Bs;Average of the blanks of S-channel and Bp; Average of the blank 
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Figure 3. Fluorescent polarization Assay, serial dilutions of 4 well-known ER 
alpha ligand were done to measure mP using the polar screen kit. Binding 
parameters were calculated by non-linear regression using GraphPad Prism 7 
software, plotted ant fitted with a one-site competition curve. The PolarScreen 
assay was used to test the ligand binding.  
 
The tested compounds were 8 different PEs (Genistein, coumestrol, daidzein, 
equol, secoisolarisinol, enterodiol and enterolactone) in which only 4 IC50 were 
calculated by the data provided by the polarization values from the tested 
concentration (from 10nM to 57pM). Coumestrol displayed the lowest IC50 
(13.75nM), secoisolarisinol, enterodiol and enterolactone needed highest 
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Figure 4. Fluorescent polarization Assay, serial dilutions of 8 well-known ER 
alpha ligand were done to measure mP using the polar screen kit data from 
equol (IC50 395nM and enterolactone (No calculated IC50) data were not 
displayed in this graph and . Binding parameters were calculate by non-linear 
regression using GraphPad Prism 7 software, plotted ant fitted with a one-site 
competition curve. The PolarScreen assay was used to test the ligand binding.  
 
ER alpha is formed by several independent domains where the LBD is solely 
responsible for the ligand binding interactions. Full-length ER alpha was 
provided with the kit, and in order to prove if the in-house recombinant LBD ER 
alpha protein was active to interact with natural ER ligands. Estradiol was used 
as a control in a range of 12 different concentration. However, it was observed 
a clear interaction and competitive binding response, the delta mP were too low 
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Figure 5. Fluorescent polarization Assay of the human LBD-ER 
recombinant protein, serial dilutions of the natural ligand 17β-estradiol that 
have a nanomolar affinity for the wild-type full-length ER alpha. However, the 
final protein concentration in the assay was no optimal to provide a desirable 
Delta mP, the purified LBD-ER alpha recombinant protein displayed is active 
and can be potentially use in future experiment and the LBD-ER beta (data no 
shown in the report) can be tested and used for downstream experiment. 
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